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ABSTRACT 
The study aim was to investigate the relationship between factors related to personal 
cancer history and lung cancer risk as well as assess their predictive utility. 
Characteristics of interest included the number, anatomical site(s), and age of onset of 
previous cancer(s). Data from the Prostate, Lung, Colorectal and Ovarian Screening 
(PLCO) Cancer Screening Trial (N = 154,901) and National Lung Screening Trial (N = 
53,452) were analyzed. Logistic regression models were used to assess the relationships 
between each variable of interest and 6-year lung cancer risk. Predictive utility was 
assessed through changes in area-under-the-curve (AUC) after substitution into the 
PLCOall2014 lung cancer risk prediction model. Previous lung, uterine and oral cancers 
were strongly and significantly associated with elevated 6-year lung cancer risk after 
controlling for confounders. None of these refined measures of personal cancer history 
offered more predictive utility than the simple (yes/no) measure already included in the 
PLCOall2014 model. 
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CHAPTER 1: INTRODUCTION 
This thesis examines the associations between personal cancer history and lung cancer 
risk. The goal of this research is to develop a better understanding of which specific 
aspects of a personal history of cancer are associated with lung cancer risk and to use this 
information to attempt to refine existing lung cancer risk prediction models. Prediction 
models are used to identify those at highest risk who are most likely to benefit from 
screening as well as smoking cessation programs for current smokers. 
In the United States, data from 2009-2011 indicates that the cumulative risk of 
developing cancer of the lung or bronchus over their lifetime is 1 in 13 for men and 1 in 
16 for women. The cumulative mortality figures are 1 in 15 for men 1 in 20 for women 
(American Cancer Society, 2013b). In Canada, estimates based on data from 2010 show 
that the lifetime risk of developing lung cancer is 1 in 12 for men and 1 in 15 for women. 
The cumulative mortality risk is 1 in 13 for men and 1 in 17 for women (Canadian 
Cancer Society’s Advisory Committee on Cancer Statistics, 2014).  
When considering males and females separately, lung cancer has the second 
highest incidence rate of all cancers in the United States after prostate cancer and breast 
cancer, respectively, with estimates of 70.1 cases per 100,000 persons per year in men 
and 50.2 per 100,000 per persons per year in women, age standardized to the 2000 U.S. 
standard population (Census P25-1130). In terms of cancer deaths, lung cancer has the 
highest age-adjusted mortality rate in both men and women; 59.8 per 100,000 and 37.8 
per 100,000 persons per year, respectively (U.S. Cancer Statistics Working Group, 2015). 
Among Canadians, the incidence rate of lung cancer in men has declined by 1.8% per 
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year since 1998 but increased in women by 1.1% per year between 1998 and 2007. 
Despite this increase, the annual incidence rate is still higher in males than females (57.6 
vs. 47.5 per 100,000 respectively, age-standardized to the 1991 Canadian population 
(Canadian Cancer Society’s Advisory Committee on Cancer Statistics, 2014)). These 
statistics are summarized in Table 1.1 but it may not be appropriate to draw comparisons 
from them due to the disagreement between the age-standardized incidence and mortality 
rates, which are consistently higher in the United States, and the lifetime risks of 
developing and dying from lung cancer which appear to reflect less favorably on the 
situation in Canada. It is likely that this anomaly is artifactual as a result of different 
methodological approaches taken to calculate the estimates. 
Table 1.1 Lung Cancer Incidence and Mortality in the United States and Canada 
 United States Canada 
 Males Females Males Females 
ASIR* (per 100,000 people per year) 70.1 50.2 57.6 47.5 
ASMR* (per 100,100 people per year) 59.8 37.8 46.3 35.6 
Lifetime Risk of Incidence  1 in 13 1 in 16 1 in 12 1 in 15 
Lifetime Risk of Mortality 1 in 15 1 in 20 1 in 13 1 in 17 
Abbreviations: ASIR: Age-standardized incidence rate; ASMR: Age-standardized mortality rate. 
*Age-standardized to the 2000 U.S. population and 1991 Canadian Standard Population, respectively. 
 
There is sufficient evidence linking tobacco smoking to the following cancer sites: oral 
cavity, nasal cavity, pharynx, larynx, esophagus, lung, stomach, pancreas, liver, kidney 
(body and pelvis), ureter, urinary bladder, cervix, ovary (mucinous), colon and rectum, 
bone marrow (myeloid leukaemia) (Secretan et al., 2009). Smoking is by far the most 
influential determinant for the development of lung cancer; a greater intensity and longer 
duration of smoking as well as a shorter quit-time all increase the risk (Tammemagi et al., 
2011). The predominance of smoking can eclipse other, more subtle but nevertheless 
important risk factors. Thus, this research was undertaken to investigate some of these 
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factors in detail, focusing on personal cancer history. The study participants were taken 
from two multi-centre screening trials in the United States, the National Lung Screening 
Trial (NLST) and the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening 
Trial. Data regarding the number, anatomical site and age of onset of previous cancers 
were collected as part of the screening trials.  
1.1 Screening and Lung Cancer-Specific Mortality  
Lung cancer is the leading cause of cancer-related mortality worldwide, responsible for 
more deaths per year than breast, prostate and colorectal cancers combined (American 
Cancer Society, 2013c). This occurs because the majority of lung cancer cases are 
diagnosed at locally/regionally advanced or metastatic stages and surgery is less likely to 
be beneficial or even feasible (American Cancer Society, 2013a). However, treatment is 
possible if the cancer is detected early enough. 49% of patients with lung cancer 
diagnosed at stage IA survive for over 5 years compared with only 5% of those diagnosed 
at stage IIIB (American Cancer Society, 2015). Lung cancer screening is being 
increasingly adopted in many areas and risk prediction models are an effective tool with 
which to determine who would most likely benefit from screening. Thus, improving risk 
prediction is important. 
Survival duration, however, is not an ideal measure of whether or not screening 
saves lives; it is inherently prone to lead-time bias, that is, when screening wrongly 
appears to improve survival length because detection occurred earlier than it otherwise 
would have, but the actual course of the disease was unaffected (Reynolds, 2012). It is 
also prone to length time bias (excessive sampling of less aggressive cases, leading to 
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overestimation of survival duration among screen-detected cases) and over-diagnosis bias 
(underestimating mortality due to the inclusion of subclinical disease that would never 
have become symptomatic were it not screened for) (Welch, Birkmeyer, Schwartz, Black, 
& Woloshin, 1999). Measuring cause-specific mortality is more appropriate. The NLST 
found a 20% reduction in lung-cancer specific mortality among those screened with low-
dose computed tomography (LDCT) compared to those screened with chest X-rays as 
well as a 6.7% reduction in all-cause mortality (Aberle et al., 2011).  
1.2 Gaps in Current Knowledge  
Studies focusing on lung cancer as a secondary or tertiary malignancy are relatively 
scarce, particularly those where the primary tumour is not of pulmonary origin. Most of 
the research into previous cancer as a risk factor for lung cancer has been concerned with 
a previous history of cancer within the family of the individual rather than the person 
themselves, and most often has focused on previous history of lung cancer. Most studies 
of subsequent primary cancer (SPC) have used population-based cancer registries to 
assess many subsequent cancer types in one comprehensive analysis rather than focusing 
on subsequent primary lung cancer (SPLC) specifically. These broad analyses usually 
lack adjustment for confounding by smoking-related factors that could be particularly 
important with respect to associations with SPLC. 
Two current prediction models (PLCOM2012 & PLCOall2014), developed using data 
from the PLCO trial, take personal history of cancer into account (Tammemagi et al., 
2013, 2014). However this predictor is included as a binary covariate in both models (yes 
vs. no), that is, having ever had or not had any previous cancer at the baseline of the 
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study (Tammemagi et al., 2013, 2014) and captures no information about the number of 
previous cancers, cancer type or age of onset. Although a personal history of cancer was 
a significant predictor of lung cancer diagnosis, more specific information may lead to 
superior prediction.  
1.3 Response to Gaps   
In order to address the research questions of this project, data from the NLST and PLCO 
trials were analyzed. The datasets from the NLST and PLCO trials contain 
comprehensive, detailed information with respect to many participant characteristics, 
including data regarding personal cancer history. Details regarding the number of 
previous cancers each participant recorded, as well as the anatomical site, and age at 
diagnosis were collected as part of the trials.  
Logistic regression models (Hosmer, Lemeshow, & Sturdivant, 2013) were used 
to obtain risk estimates for these characteristics as predictors of future lung cancer in the 
individual. Effect sizes were estimated using odds ratios (ORs). Data on smoking status, 
intensity, duration and quit-time for participants facilitated controlling for smoking 
exposures. The same modeling technique was used to build prediction models that 
incorporated new factors in addition to predictors established in previous models. The 
utility of the new variables was determined based on the predictive performance of 
models that included them; discrimination (area under the receiver-operating-
characteristic curve [AUC]) and calibration (Spiegelhalter’s statistic, a component of the 
Brier score) were assessed. 
1.4 Study Aims and Research Questions 
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In general terms this study aimed to develop an understanding of the relationship between 
personal cancer history and lung cancer risk. More specifically, the goal was to evaluate 
the independent risk of lung cancer associated with having been previously diagnosed 
with commonly occurring cancers, number of previous cancers and age at diagnosis, and 
to use this information to refine risk prediction modeling for lung cancer, where possible. 
In order to achieve these aims, the following research questions will be addressed: 
1. Type of cancer 
Are any specific types of previous cancers strong independent predictors of subsequent 
lung cancer?  
2. Number of cancers 
Is the number of previous cancers an important predictor of future lung cancer? 
3. Age at diagnosis  
Is being diagnosed with cancer before age 60 years associated with future lung cancer 
risk more strongly than diagnosis at 60 years or older? 
4. Predictive performance 
Do any of these associations lead to improved lung cancer risk prediction models? 
1.5 Conclusion 
There are a number of reasons why this research is important. Firstly, lung cancer 
represents a major global health concern and the NLST has demonstrated the ability of 
screening with computed tomography to significantly reduce lung cancer mortality, but 
continual improvements in targeting high-risk individuals is crucial since screening 
individuals at low risk has been shown to be ineffective, inefficient, and potentially 
harmful to the patient (Kovalchik et al., 2013). Secondly, the focus on a history of 
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previous cancer in the current study is justified; Bae et al. (Bae et al., 2011) found that 
93% of lung cancers as a SPC and 61% of lung cancers as recurrences were detected by 
computed tomography and treatment can be both feasible and effective for those with 
lung cancer as a second cancer, if the cancer is detected early enough, with a 5-year 
survival rate of 77% (Bae et al., 2011). 
This research builds on lung cancer prediction models established using data from 
the NLST and PLCO trials that have demonstrated high discrimination and calibration 
but have the potential to be further refined and improved. In this study, detailed 
prospective data, lengthy follow-up and a large sample size consisting of both smokers 
and non-smokers facilitated the investigation of multiple risk factors that are relatively 
uncommon while maintaining a reasonable degree of statistical power. This project was 
able to explore the effect of a personal history of cancer with respect to lung cancer risk 
in greater detail than in previous studies while being able to adjust for other known risk 
factors in a way that was superior to past studies due to quality and detail of information. 
The findings from these analyses may facilitate improvements to currently existing lung 
cancer risk prediction models as well as provide valuable insights into lung cancer 
carcinogenesis. 
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CHAPTER 2: REVIEW OF THE LITERATURE 
2.1 Overview 
This chapter provides a background and context for the current study as well as offering 
the rationale for the research; the main focus is placed on the factors most pertinent to 
this study. The association between previous cancer and subsequent primary cancer 
(SPC) in general is commented on but the main focus of the review is on associations 
with subsequent primary lung cancer (SPLC). The standardized incidence ratios (SIRs) 
from the studies discussed in this section are summarized along with their corresponding 
sample sizes and adjustment criteria in Table 2.1. An SIR expresses the incidence within 
a defined study population relative to what would be expected if the incidence seen 
among a comparison group (most often the general population) were applied to the 
population being studied. If the number of observed cases equals the number expected, 
the SIR is 1. An SIR greater than 1 indicates a greater than expected number of cases and 
conversely, fewer than expected would give an SIR less than 1 (Aschengrau & Seage, 
2008). 
An overview of the current state of screening for lung cancer is provided and 
finally, the process of risk prediction model development is outlined as well as an 
overview of notable risk prediction models for lung cancer. 
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 Table 2.1 - Summary of standardized incidence ratios (SIRs) from studies investigating associations between 
previous cancer and SPLC by initial cancer type 
Abbreviations: Adc: Adenocarcinoma; BCC: Basal cell carcinoma; CI: confidence interval; N: Number; SPLC (subsequent primary lung cancer);  
SSC: Squamous cell carcinoma. 
* SCC; † Adc; § in situ; ‖ Invasive; ¶ BCC. 
 
Initial cancer type Study N SIR (95% CI) Adjustment criteria 
Breast (Hemminki et al., 2005) 3,409 males 1.26 (0.96 – 1.61) Age, calendar year, registry 
 (Andersson, Jensen, Engholm, & Henrik Storm, 2008) 53,418 
females 
1.0 (0.9 – 1.1) Sex, age, calendar period 
 (Utada, Ohno, Hori, & Soda, 2014) 174,477 1.41 (1.13 – 1.73) Sex, age group, calendar year 
Digestive     
Colorectal (Hemminki, Li, & Dong, 2001) 68, 104 1.90 (0.36 – 4.66) Age, sex 
 (Phipps, Chan, & Ogino, 2013) 170,159 1.14 (1.10 – 1.18) Sex, age, calendar year, race 
 (Jégu et al., 2014) 289,967 1.16 Age, sex, year of index cancer 
Esophageal (Chuang, Hashibe, et al., 2008) 52,589 1.55 (1.28 – 1.87)* 
0.91 (0.60 – 1.32)† 
Age, sex, calendar year 
 (Zhu et al., 2012) 24,557 3.19 (2.12 – 4.61) Sex, age, race and calendar year 
 (Jégu et al., 2014) 160, 807 
males 
4.25  Age, sex, year of index cancer 
 (Utada et al., 2014) 174,477 1.39 (1.02 – 1.85) Sex, age group, calendar year 
Endocrine     
Thyroid (Rubino et al., 2003) 6,841 1.0 (0.6 – 1.4) Sex, calendar year, age 
 (Canchola, Horn-Ross, & Purdie, 2006) 10,932 
females  
1.0 (0.6 – 1.4) Sex, age and calendar period 
 (Verkooijen, Smit, Romijn, & Stokkel, 2006) 282 0.46 (0.08 – 1.15) Age, sex 
 (A. P. Brown et al., 2008) 30,278 0.85 (0.75 – 0.96) Age, sex, calendar year 
 (C.-H. Lu et al., 2013) 19,068 1.57 (1.25 – 1.95) Age, sex, calendar year 
 (Utada et al., 2014) 174,477 1.83 (1.31 – 2.49) Sex, age group, calendar year 
Genitourinary     
Kidney (Czene & Hemminki, 2002) 9,344 1.36 (1.12 – 1.47) Sex, calendar year, age 
 (Utada et al., 2014) 174,477 1.29 (1.13 – 1.73) Sex, age group, calendar year 
Prostate (Thellenberg, Malmer, Tavelin, & Grönberg, 2003) 135,713 1.05 (0.99 – 1.12) Calendar period, age 
 (Hinnen et al., 2011) 1,888 0.48 (0.32 – 0.71) Age, calendar year 
 (Utada et al., 2014) 174,477 0.85 (0.71 – 0.99) Age group, calendar year 
     
Testicular (Travis et al., 2005) 40,576 1.5 (1.2 – 1.7) Area, age, calendar year 
Gynecologic     
Cervical (Hemminki, Dong, & Vaittinen, 2000) 117, 830 2.81 (2.43 – 3.21)§ 
2.17 (2.00 – 2.34)‖ 
Age, calendar period 
 (Jégu et al., 2014) 289,967 4.44 Age, year of index cancer 
Uterine (Koivisto-Korander et al., 2012) 8,606 1.73 (1.04 – 2.70) Calendar year, age at diagnosis 
 (Jégu et al., 2014) 289,967 1.62  Age, year of index cancer 
 (Utada et al., 2014) 174,477 1.91 (1.50 – 2.38) Age group, calendar year 
Head and Neck (Chuang, Scelo, et al., 2008) 99,257 3.30 (3.19 – 3.41) Sex, calendar year, registry 
 (Jégu et al., 2014) 160, 807 
males 
8.71 Age, sex, year of index cancer 
  129,160 
females 
18.81 Age, sex, year of index cancer 
Laryngeal (Morris, Sikora, Hayes, Patel, & Ganly, 2011)  75,087 4.07 (3.92 – 4.22) Age, sex, race, calendar period 
 (Chen et al., 2011) 63,720 2.60 (2.04 – 3.25) Age, calendar year 
 (Utada et al., 2014) 174,477 1.41 (1.13 – 1.73) Sex, age group, calendar year 
Oropharyngeal (Morris et al., 2011) 75,087 4.86 (4.54 – 5.20) Age, sex, race, calendar period 
 (Chen et al., 2011) 63,720 1.56 (1.34 – 1.80) Age, calendar year 
Nasopharyngeal (Scélo et al., 2007) 8,947 1.35 (0.89 – 1.96) Age, sex, calendar period 
 (Chen et al., 2011) 63,720 1.12 (0.90 – 1.38) Age, calendar year 
Hematologic     
Hodgkin  
lymphoma 
(Jégu et al., 2014) 160, 807 
males 
4.02 Age, sex, year of index cancer 
  129,160 
females 
4.14 Age, sex, year of index cancer 
Non-Hodgkin  
lymphoma 
(Mudie et al., 2006) 2,456 1.6 (1.1 – 2.3) Age, sex, calendar year 
 (Morton et al., 2010) 43,145 1.19 (1.09 – 1.30)  Age, sex, ethnicity, calendar year 
 (Jégu et al., 2014) 289,967 1.62 Age, sex, year of index cancer 
Skin     
Non-melanoma (Nugent, Demers, Wiseman, Mihalcioiu, & Kliewer, 2005) 43,275 1.09 (1.00 – 1.19)¶ 
 
Age, sex 
 (Cantwell et al., 2009) 14,442 1.15 (0.97 – 1.33)¶ Age 
  6,401 1.05 (0.81 – 1.30)*  
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2.2 Major Risk Factors for Lung Cancer  
Numerous factors that are associated with the development of lung cancer have been 
identified. Cigarette smoking (both intensity and duration) is by far the most important 
risk factor and exposure to radon gas is believed to be the next leading cause of lung 
cancer in North America and Europe (American Cancer Society, 2013a). Around 85% of 
lung cancer cases are attributable to cigarette smoking (Canadian Cancer Society’s 
Advisory Committee on Cancer Statistics, 2014).  
Smoking cessation can decrease the risk substantially but not to that of never-
smokers (Peto et al., 2000). Other risk factors include secondhand smoke, asbestos 
exposure, air pollution as well as having a history of lung cancer in the family (American 
Cancer Society, 2013c). Age, race/ethnicity, education level, body-mass index (BMI), 
and previous diagnosis of chronic obstructive pulmonary disease (COPD) have all be 
found to be associated with lung cancer risk among smokers (Tammemagi et al., 2013). 
A summary of several other key risk factors for lung cancer that might serve as useful 
predictors is presented in Supplemental Table S1 of reference Tammemagi & Lam (2013) 
(Tammemagi & Lam, 2013). 
2.2.1 Previous cancer  
It has been established that developing cancer can be associated with an increased risk of 
SPC. For all cancers combined, both male (SIR = 1.22; 95% CI: 1.20 – 1.24) and female 
(SIR = 1.36; 95% CI: 1.33 – 1.39) cancer survivors have been found to have a significant 
excess risk of developing a second cancer relative to the general population (Youlden & 
Baade, 2011). This association is particularly apparent among smokers.  
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Smoking is an independent risk factor for several SPC even after controlling for 
confounders, including a smoking-related first cancer (Tabuchi et al., 2013). Tabuchi and 
colleagues estimated that smokers had a 59% increased risk SPC in general and 102% 
increased risk of smoking-related SPC compared to never-smokers (Tabuchi et al., 2013). 
Compared with never-smokers, current smokers of ≥ 20 cigarettes per day have been 
found to be associated with increased second smoking-associated cancer risk among 
survivors of stage I lung cancer (HR = 3.26; 95% CI: 0.92 to 11.6), bladder (HR = 3.67; 
95% CI: 2.25 to 5.99), head/neck (HR = 4.45; 95% CI: 2.56 to 7.73), and kidney (HR = 
5.33; 95% CI: 2.55 to 11.1) cancers (Shiels et al., 2014). 
For SPLC specifically, ever smokers who have survived cancer have a 
significantly elevated risk of compared to never-smokers regardless of the site of the first 
cancer (Tabuchi et al., 2013). The increased risk is likely attributable to factors such as 
similar disease etiologies, genetic susceptibility and the effects of treatment procedures 
undergone for the initial cancer, particularly if exposed to radiation (Youlden & Baade, 
2011). In terms of the prognostic significance, lung cancer patients who have had a 
previous primary cancer have comparable prognoses and respond similarly to treatment 
as those whose lung cancer is their first malignancy (Koppe et al., 2001). Quitting 
smoking immediately after cancer diagnosis can significantly reduce the risk of 
developing SPC, after adjusting for confounding factors (Tabuchi et al., 2013).  
Finally, it should be noted that second primary malignancies can either be classed 
as synchronous (cancers detected or treated at the same time as the original (index) 
cancer) or metachronous (cancers detected sometime after the initial primary cancer that 
are physically distinct and separate) (Martini et al., 1995). Naturally, this is of most 
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concern when discussing SPLC among lung cancer survivors but the following 
discussion will focus on previous cancers at sites other than the lung. 
2.2.1.1 Previous Cancer Sites associated with SPLC 
Breast 
The risk of developing a SPC following breast cancer is particularly important since it is 
the most commonly diagnosed cancer among women in Canada, most of whom (88%) 
survive their diagnosis (Canadian Cancer Society’s Advisory Committee on Cancer 
Statistics, 2014), consequently increasing the opportunity of future cancer. Lung cancers 
account for approximately 5% of SPC among breast cancer survivors (Mariotto, 
Rowland, Ries, Scoppa, & Feuer, 2007). No evidence of an increased SPLC risk, relative 
to the general population, has been observed for male breast cancer survivors (Hemminki 
et al., 2005). 
Several population-based studies have evaluated the risk of SPLC after breast 
cancer in women. Utada and colleagues reported a 41% increased risk of lung cancer 
following previous breast cancer (SIR 95% CI: 1.13- 1.73) among Japanese survivors, 
after controlling for age group and calendar year (Utada et al., 2014). A summary of 
relative risks (RRs) found in population cancer registry studies of SPC among breast 
cancer survivors is presented by Evans et al.; RRs for SPLC relative to the general 
population ranged from 1.4 in Denmark to 1.7 in Connecticut, and the USA (in those 
diagnosed with breast cancer before age 45) (Evans et al., 2001). The increased risk of 
SPLC associated with prior breast cancer were all statistically significant at an alpha level 
of 0.05 (Ewertz & Mouridsen, 1985; Harvey & Brinton, 1985; Teppo, Pukkala, & Saxén, 
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1985; Volk & Pompe-Kirn, 1997). Among a cohort of 145,677 women diagnosed with 
breast cancer between 1961 and 1996, Evans and colleagues reported an increased SPLC 
risk in those initially diagnosed before age 50 (SIR = 1.49; 95% CI: 1.26 – 1.78) but a 
protective effect was seen among those diagnosed between 50-84 (SIR = 0.68; 95% CI: 
0.62 – 0.74) (Evans et al., 2001). These estimates were adjusted for age and calendar 
year, but not for smoking. Raymond and Hogue (2006) also present SIRs for SPLC 
stratified by age at diagnosis in their analysis of 335,191 females with breast cancer and 
found that SPLC risk was positively associated with younger age at diagnosis (SIRs of 
6.7, 1.31 and 1.24 for age groups of 30-39, 40-49 and 50-59, respectively) (Raymond & 
Hogue, 2006). 
In a further analysis of 525,527 women using data taken from 13 population-
based cancer registries in Europe, Canada, Australia and Singapore, Mellemkær and 
colleagues reported a statistically significantly increased risk of SPLC, after adjustment 
for 5-year age group and calendar period (Mellemkjær et al., 2006). SPLC risk was 
highest for women with premenopausal breast cancer diagnosis (SIR = 2.12; 95% CI: 
1.92 – 2.33) compared to perimenopausal (SIR = 1.53; 95% CI: 1.42 – 1.64) or 
postmenopausal (SIR = 1.05; 95% CI: 1.00 – 1.10) (Mellemkjær et al., 2006). A lack of 
an association with SPLC was reported among a Danish cohort of 53,418 breast cancer 
patients (SIR = 1.0; 95% CI: 0.9 – 1.1) after adjustment for sex, 5-year age group and 
calendar period. However, SIRs varied by follow-up interval since breast cancer 
diagnosis, from 0.8 (95% CI: 0.7 – 0.9) for 1-9 years, to 2.9 (1.6 – 4.1) for 20+ years; the 
trend was statistically significant (Andersson et al., 2008). SPLC risk was highest for 
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individuals diagnosed before age 50 years (SIR = 1.5; 95% CI: 1.2 – 1.9) (Andersson et 
al., 2008).  
Women who received radiation treatment for breast cancer have been shown to be 
at a 1.5- to 3-fold increased risk for subsequently developing lung cancer compared with 
women who did not receive radiation (Neugut et al., 1993; Zablotska & Neugut, 2003). 
The finding that lung cancers after breast cancer therapy are most frequently found in the 
ipsilateral lung supports the contributing role of radiation to the risk (Zablotska & 
Neugut, 2003). A systematic review and meta-analysis of second non-breast cancer in 
those who previously underwent radiotherapy for breast cancer reported a pooled RR for 
SPLC of 1.23 (95% CI: 1.07 – 1.43), adjusted for smoking status and adjuvant therapy, 
compared to those who did not receive radiotherapy (Grantzau & Overgaard, 2014).  
There is growing evidence from recent studies that women who smoke have an 
increased risk of breast cancer, particularly if they start smoking before they have their 
first child. Both a higher intensity and a longer duration are associated with elevations in 
risk (Dossus et al., 2014; Gaudet et al., 2013). Controlling for smoking status alone could 
be an inadequate way of adjusting for the effects of smoking. 
Digestive 
Colorectal 
An elevated risk of SPLC has been found among those with previous colorectal 
cancer relative to the general population (SIR = 1.14; 95% CI: 1.10 – 1.18) after 
adjustment for age (5 year grouping), sex, and race (black, white, other) (Phipps et al., 
2013). This finding was replicated by Jégu and colleagues (SIR = 1.16) after adjustment 
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for age, year of first cancer diagnosis (Jégu et al., 2014). However, Hemminki and 
colleagues (2001) found no statistically significant relative increase in risk SPLC among 
68,104 cases of colorectal cancer, relative to the general population, regardless of follow-
up length (< 1 year, 1 – 10 years or > 10 years) (Hemminki, Li, & Dong, 2001).  
An increased risk of SPLC after radiotherapy treatment for rectal cancer was seen 
among participants of the Swedish Rectal Cancer Trial, compared to those treated with 
surgery alone, but it was not statistically significant (RR = 4.36; 95% CI: 0.51 – 37.33) 
(Birgisson, Påhlman, Gunnarsson, & Glimelius, 2005). 
Esophageal 
Among survivors of esophageal cancer, subsequent lung cancer risk was found to be 
significantly elevated (SIR = 3.19; 95% CI: 2.12–4.61, adjusted for sex, race, age and 
calendar year) compared with the general population (Zhu et al., 2012). A similar 
increase in SPLC risk among male esophageal cancer survivors, relative to the general 
population, was published by Jégu and colleagues (SIR = 4.25) after adjustment for age, 
sex, year of first cancer diagnosis (Jégu et al., 2014). SIRs for SPLC by histological type 
of esophageal cancer were reported in a pooled analysis of 13 cancer registries; SPLC 
risk was elevated for squamous cell carcinoma (SCC) of the esophagus (SIR = 1.55; 95% 
CI: 1.28 – 1.87), but not for adenocarcinoma (AdC) (SIR = 0.91; 95% CI: 0.60 – 1.32) 
and only persisted for SPLC diagnosed at least one year after esophageal cancer 
diagnosis (Chuang, Hashibe, et al., 2008). Utada and colleagues reported a 39% increased 
risk of lung cancer following previous esophageal cancer (SIR 95% CI: 1.02- 1.85) 
among Japanese survivors, after controlling for sex, age group and calendar year (Utada 
et al., 2014). 
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Gastric 
Most studies investigating SPCs have not reported the risk of SPLC specifically 
among survivors of gastric cancer, but the frequency of SPC types following gastric 
cancer was reported for 2,250 patients in Japan by Ikeda and colleagues (2002). The lung 
was the most common site of SPC (46.9%) but no comparison relative to a control group 
was presented (Ikeda et al., 2002).  
Endocrine 
Thyroid 
The risk of SPC among thyroid cancer survivors was evaluated by pooling data from 
three major Swedish, French and Italian cohorts; among 6,841 patients, 32 developed 
SPLC but no statistically significant increase was seen compared to those with no 
previous thyroid cancer after adjustment for sex, age and calendar year (SIR = 1.0; 95% 
CI: 0.6 – 1.4) (Rubino et al., 2003). A lack of association with SPLC was reported for 
both male (n = 146) or female (n = 729) thyroid cancer patients in France after 
adjustment for sex, age and 5-year calendar period (Berthe et al., 2004). An analysis 
specific to women with papillary thyroid cancer (N=10,932) also failed to find any 
association with SPLC, relative to the general population (SIR = 1.0; 95% CI: 0.6 – 1.4) 
(Canchola et al., 2006).  
A protective effect for SPLC relative to the general population was reported by 
Verkooijen and colleagues (2006) but their sample size was relatively small (n=282) 
(Verkooijen et al., 2006). However, this was also observed in a much larger study (N=30, 
278) of SPC up to 30 years after treatment of thyroid cancer (SIR = 0.85; 95% CI: 0.75 – 
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0.96) relative to the general population, controlling for age, sex and calendar year (A. P. 
Brown et al., 2008). Only one study of SPLC among 19,068 Asian survivors of thyroid 
cancer reported an elevated risk (SIR = 1.57; 95% CI: 1.25 – 1.95, adjusted for age, sex 
and calendar year) (C.-H. Lu et al., 2013). 
Sawka and colleagues (2009) assessed the effect of treatment with radioactive 
iodine with respect to SPC risk after thyroid cancer. The magnitude of the association for 
SPLC relative to those not treated with radioactive iodine was suggestive of a clinically 
relevant increase but the association was not statistically significant (RR = 1.50; 95% CI: 
0.86 – 2.60) (Sawka et al., 2009). 
Genitourinary 
Kidney 
Studies of SPC after cancer of the kidney do not typically include estimates of SPLC but 
an increased risk of SPLC was seen among cases of kidney cancer reported to the 
Swedish Family Cancer Database, relative to general population after controlling for sex, 
calendar year and age (SIR = 1.36; 95% CI: 1.13 – 1.61) (Czene & Hemminki, 2002). 
Utada and colleagues reported a 29% increased risk of lung cancer following previous 
cancer of the kidney, bladder or urinary tract (SIR 95% CI: 1.12 – 1.47) among Japanese 
survivors, after controlling for sex, age group and calendar year (Utada et al., 2014). 
Prostate 
The risk of SPC is particularly relevant for prostate cancer survivors as men are being 
diagnosed at earlier stages and younger ages than in the past (Brawley, 2012). Thus, 
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patients may receive treatment earlier and are surviving longer, increasing the period in 
which subsequent cancer can develop.  
In a large population-based study of all cases of prostate cancer reported to the 
Swedish Cancer Registry between 1958-1996 (N=135,713), Thellenberg and colleagues 
reported no evidence of an association with SPLC relative to general population overall 
(SIR = 1.05; 95% CI: 0.99 – 1.12), but an elevated risk was seen among those diagnosed 
with SPLC up to five months after their prostate cancer diagnosis (SIR = 3.49; 95% CI: 
3.14 – 3.86), most likely due to heightened surveillance during that time period 
(Thellenberg et al., 2003). In contrast, evidence of a statistically significant protective 
effect on SPLC risk among a cohort of 1,888 prostate cancer patients, relative to the 
general population (SIR = 0.48; 95% CI: 0.32 – 0.71) after controlling for age and 
calendar year (Hinnen et al., 2011). This result is supported by the study of Japanese 
cancer survivors, in which Utada and colleagues reported an SIR for SPLC of 0.85 (95% 
CI: 0.72 – 0.99) among prostate cancer survivors (Utada et al., 2014). It has been 
suggested that the ‘protective’ effects reported in several other studies (Kleinerman, 
Liebermann, & Li, 1985; Liskow et al., 1987; Pawlish, Schottenfeld, Severson, & 
Montie, 1997) could be explained by underreporting in survivors who live to an elderly 
age (Pickles & Phillips, 2002) as well as a lower than average frequency of smokers 
among prostate cancer survivors compared to the general population, since curative 
treatments for prostate cancer could be contraindicated by smoking-related comorbidities 
(Hinnen et al., 2011). 
A study by Brenner and colleagues found that patients who received radiation 
treatment for prostate cancer had a significantly increased risk for subsequent lung cancer 
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compared with those treated who received surgery (RR = 1.11; 95% CI: 1.01 – 1.21) after 
adjustment for age at diagnosis (Brenner, Curtis, Hall, & Ron, 2000), a finding later 
replicated by Moon and colleagues (OR = 1.25; 95% CI: 1.13 – 1.37) (Moon, 
Stukenborg, Keim, & Theodorescu, 2006). 
Testicular 
Among a population of 40,576 survivors of testicular cancer, 256 developed SPLC. The 
SIR compared with the general population was 1.5 (95% CI: 1.2 – 1.7) after adjustment 
for registration area, 5-year age group and calendar year (Travis et al., 2005). However, 
among cases of testicular cancer in the Swedish Family Cancer Database (N= 4,650) risk 
of SPLC was not associated with previous testicular cancer of any histological type, 
regardless of follow-up length, after adjustment age, period, residence and occupation 
(Dong, Lönnstedt, & Hemminki, 2001). 
The extent to which any association with SPLC may be confounded by smoking 
is uncertain, but several studies have failed to demonstrate an association between 
smoking and testicular cancer risk (L. M. Brown, Pottern, & Hoover, 1987; Henderson, 
Benton, Jing, Yu, & Pike, 1979; Oliver, 1994). 
Gynecologic 
Cervical 
A study by Arnold and colleagues found that the majority of SPCs diagnosed following 
cervical cancer were smoking-related (SIR = 1.8; 95% CI: 1.4 – 2.2); among the 12,048 
patients in their study, 676 developed a SPC during the study period, of which 147 
(21.7%) were lung cancers (SIR = 4.7; 95% CI: 4.0 – 5.5, adjusted for 5-year age group 
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and calendar year). The median follow-up for smoking-related cancers was 5 years 
(Arnold et al., 2014). In the population study by Jégu and colleagues (2014), the risk of 
SPLC among females with cervical cancer was highly elevated (SIR = 4.44) relative to 
the general population, after adjustment for age and year of first cancer diagnosis. 
A large population-based analysis of the Swedish Family-Cancer Database 
assessed SPC after in situ (N=117, 830) and invasive cervical cancers (N=17,556). SIRs 
for SPLC, relative to the general population, were elevated for both types but was highest 
for invasive (2.81; 95% CI: 2.43 – 3.21) versus in situ (2.17; 95% CI: 2.00 – 2.34). 
Estimates were adjusted for age and calendar period (Hemminki, Dong, & Vaittinen, 
2000).  
Cervical cancer survivors treated with radiotherapy were at higher risk for a 
second tumour compared to those who were not, especially at smoking-related sites 
(incidence rate ratio (IRR) = 1.6 (95% CI:1.2 – 2.3)) (Arnold et al., 2014). An increased 
lung cancer risk was also observed among a cohort of cervical cancer survivors not 
treated with radiation suggests that common etiological factors other than radiation 
exposure such as tobacco use are likely to be attributable (Chaturvedi et al., 2007). 
Uterine  
As part of an international study of SPC using data from 13 cancer registries, an 
increased risk of SPLC (SIR = 1.73; 95% CI: 1.04 – 2.70, adjusted for calendar period 
and age at diagnosis) was seen among 8,606 cases of uterine sarcomas, compared to the 
general population (Koivisto-Korander et al., 2012).  
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Jégu and colleagues reported an elevated risk of SPLC among females with 
uterine cancer (SIR = 1.62) relative to the general population, after adjustment for age 
and year of first cancer diagnosis (Jégu et al., 2014). An even greater, 91% increased risk 
for SPLC (SIR 95% CI: 1.50 – 2.38) was reported among Japanese females, after 
controlling for age group and calendar year (Utada et al., 2014). 
Head and Neck 
Patients with head and neck SCC are at highly elevated risk of SPC most commonly 
within the head and neck, lung, and esophagus (León et al., 1999; Sturgis & Miller, 1995; 
Yamamoto, Shibuya, Yoshimura, & Miura, 2002). Carcinoma of the lung has also been 
reported as the most common SPC among laryngeal cancer survivors (Licciardello, Spitz, 
& Hong, 1989; Yamamoto et al., 2002). 
SIRs of 4.86 (95% CI: 4.54 – 5.20) and 4.07 (3.92–4.22) for SPLC have been 
reported for survivors of oropharyngeal and laryngeal cancers respectively, after 
adjustment for age, sex, race and calendar period (Morris et al., 2011). Jégu and 
colleagues (2014) also reported the risk of SPLC, relative to the general population, in 
those who were diagnosed with head and neck cancers; the SIRs were 8.71 for males and 
18.81 for females after adjustment for age, sex, year of first cancer diagnosis (Jégu et al., 
2014). In their study of 63,720 Taiwanese cancer survivors, Chen and colleagues (2011) 
reported an increased SPLC risk following laryngeal (SIR = 2.05; 95% CI: 1.69 – 2.45) 
or oropharyngeal cancer (SIR = 1.56; 95% CI: 1.34 – 1.80) but not nasopharyngeal 
carcinoma (SIR =  1.12; 95% CI: 0.90 – 1.38) (Chen et al., 2011). The majority of 
nasopharyngeal carcinoma cases in Asia are strongly associated with prior Epstein-Barr 
infections (Abdel-Hamid, Chen, Constantine, Massoud, & Raab-traub, 1992) so the 
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location may have influenced the result reported by Chen et al.. However, in an 
international multicenter study by Scélo and colleagues (2007), no statistically significant 
increase in SPLC risk was seen for survivors of nasopharyngeal cancer from either 
Singapore (SIR = 0.65; 95% CI: 0.13 – 1.90) or Australia, Canada, Europe (combined) 
(SIR = 1.18; 95% CI: 0.43 -2.56) (Scélo et al., 2007).    
In their pooled analysis of 13 cancer registries (N=99,257) by Chuang and 
colleagues (2008), the overall SIR for SPLC among those with head and neck cancer was 
3.30 (95% CI: 3.19 – 3.41) after adjustment for sex, year and registry, relative to the 
general population (Chuang, Scelo, et al., 2008). The elevation in risk was especially 
pronounced if the person’s head and neck cancer was diagnosed before age 56 (SIR = 
4.46; 95% CI: 4.17 – 4.77). The SIR declined successively at each older age group (p < 
.0001 for each age group compared to the youngest category using Poisson regression) 
(Chuang, Scelo, et al., 2008). 
Chen and colleagues also found that SPLC risk was highest in patients whose 
initial cancer was diagnosed before age 50 years among survivors of oropharyngeal 
cancer. SIRs for SPLC were 5.41, 1.91 and 0.98 for those whose initial age of onset was 
< 50 years, 50-59 and 60-69, respectively. Corresponding estimates for survivors of 
laryngeal cancer were 4.88, 3.93 and 1.90 (Chen et al., 2011). 
Hematologic 
Hodgkin Lymphoma (HL)  
Compared to the general population, survivors of HL have a have a 2 to 3-fold risk of 
developing a second cancer, including lung cancer. This elevated risk is likely 
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attributable to radiation treatments in the chest region as well as chemotherapy with 
alkylating agents (American Cancer Society, 2012). 
Jégu and colleagues (2014) reported the risk of SPC, relative to the general 
population using data from ten French population-based cancer registries (N = 289,967). 
In those who were diagnosed with Hodgkin lymphoma, the SIR for SPC of the lung, 
bronchus and trachea was 4.02 for males and 4.14 for females after adjustment for age, 
sex, year of first cancer diagnosis (Jégu et al., 2014).   
A meta-analysis of 21 studies investigating SPLC risk among HL survivors 
calculated a pooled RR for SPLC of 4.62 (95% CI: 3.18 – 6.70, I 2 = 98%). This estimate 
was positively associated with sample size, sex distribution, institutional vs. population-
based datasets, and the use of radiotherapy or combined modality therapy. No association 
with risk was seen for age at diagnosis (Ibrahim et al., 2013). I2 expresses the degree of 
inconsistency across studies used in a meta-analysis – i.e. how much of the variation 
between them is attributable to heterogeneity as opposed to chance (Higgins, Thompson, 
Deeks, & Altman, 2003). In this case, 98% indicates very high disagreement between the 
studies, thus pooling their results may not have been appropriate. The heterogeneity could 
be due to diversity between participants or methodological factors such as varying 
degrees of measurement error. 
Travis et al. conducted a case–control study of 222 cases of lung cancer and 444 
matched controls in individuals previously treated for HL; lung cancer risk increased with 
radiation dose (p < .001) for doses of 30 Gy or higher, relative to those who received <5 
Gy of radiation (Travis et al., 2002). For solid tumours, typical doses are 60 – 80 Gy for 
curative radiotherapy, and 45-60 for adjuvant therapy, delivered in 1.8-2 Gy fractions 
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(Chung, 2008; Nieder & Baumann, 2011; Sonett et al., 2004; UK National Collaborating 
Centre for Cancer, 2009).   
A case–control study by Travis and colleagues (2002) in which the reference 
group comprised HL patients who had minimal radiation exposure, those treated with 
only alkylating agent chemotherapy experienced a fourfold increased lung cancer risk. 
This increased to sevenfold in those treated with 5 Gy or more of radiation (Travis et al., 
2002). Relative risks of 16.8 and 20.2, respectively, were seen for in those patients who 
also smoked at least one pack of cigarettes per day. For cigarette smokers (at least one 
pack per day) who had also received both alkylating chemotherapy and 5 Gy or more of 
radiation to the area in question, the relative risk for subsequent lung cancer was 49.1 
(Travis et al., 2002). 
Non-Hodgkin Lymphoma (NHL) 
A British cohort study of 2,456 patients with NHL found a significantly elevated risk of 
SPLC (SIR = 1.6; 95% CI: 1.1 – 2.3, adjusted for age, sex and calendar year) compared 
to the general population (Mudie et al., 2006). Morton and colleagues evaluated the risk 
of second cancers among 43,145 survivors of NHL using SEER registries and reported 
statistically significant increased risk of lung cancer (SIR = 1.19, adjusted for 5-year age 
group, sex, ethnicity and calendar year) compared to the general population (Morton et 
al., 2010).  
In their analysis of ten French population-based cancer registries (all patients 
diagnosed with cancer between 1989 and 2004), Jégu and colleagues also reported an 
elevated risk of SPLC relative to the general population (SIR = 1.62), among male 
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patients with NHL after adjustment for age, sex, year of first cancer diagnosis (Jégu et al., 
2014). 
Skin 
Among 21 studies of SPC risk following non-melanoma skin cancer, pooled relative risks 
for SPLC specifically were 1.23 (95% CI: 1.13 – 1.33), 1.13 (95% CI: 1.01 – 1.27) and 
1.34 (95% CI: 1.22 – 1.47) in survivors of non-melanoma skin cancer of any kind, basal 
cell carcinomas (BCC) and SCC, respectively (Wheless, Black, & Alberg, 2010). 
However, a 2014 meta-analysis of SPC among non-melanoma skin cancer survivors, 
comprising over 350,000 patients from population-based cancer registries across several 
continents, found no evidence to suggest an elevated SPLC risk after pooling study-
specific estimates (pooled RR = 0.86; 95% CI: 0.63 – 1.18, I2 71%) (Caini et al., 2014).  
In two US cohorts, the Health Professionals Follow-up Study (HPFS) and the 
Nurses’ Health Study (NHS) (N = 46,237), Song and colleagues (2013) found an 
increased SPLC risk following non-melanoma skin cancer in women (RR = 1.32; 95% 
CI: 1.14 – 1.52) but not in men (RR = 0.99; 95% CI: 0.79 – 1.24); estimates were 
adjusted for age, BMI, physical activity, smoking status, smoking intensity, multi-vitamin 
use, UV-index in place of residences, and menopausal status, hormone replacement 
therapy use in women (Song et al., 2013). A study of patients with basal cell carcinoma 
of the skin in Northern Ireland (N=14,442) found no evidence of elevated SPLC risk 
relative to the general population in either women or men, after controlling for age 
(Cantwell et al., 2009). A small increase in SPLC risk following basal cell carcnioma 
(BCC) was observed by Nugent and colleagues in their analysis of all 43,275 non-
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melanoma skin cancer cases reported between 1956 and 2000 in Manitoba (SIR = 1.09; 
95% CI: 1.00 – 1.19) but not for SCC (Nugent et al., 2005). 
2.2.1.2 Cancer Treatment  
A well-established potential cause of cancer is exposure to radiation, including the 
radiation commonly used to treat cancer itself (American Cancer Society, 2012). The risk 
of developing a radiation-induced second primary cancer (RISPC) is dependent upon 
factors such as the dose of radiation received, the anatomical site treated and the age of 
the patient at the time of treatment (American Cancer Society, 2012). Increased risks 
have been associated with several tumour sites, including the lungs (Travis, 2006), which 
usually occur 10 or more years after treatment (Boice Jr, Land, & Preston, 1996). A 
ranked summary of the carcinogenic effects of radiation exposure on various tissues is 
presented by Travis (Travis, 2006). Solid tumours induced by radiotherapy include lung 
cancers. Some chemotherapy treatments have also been linked to the development of 
solid tumours (American Cancer Society, 2012). 
Lung cancer risk increases in an approximately linear fashion with radiation dose 
(Preston et al., 2009; Thompson et al., 1994). Dose-response relationships with SPLC 
have been reported among patients given thoracic radiotherapy for Hodgkin lymphoma 
(Gilbert et al., 2009; Travis et al., 2002; van Leeuwen et al., 1995) and breast cancer 
(Inskip, Stovall, & Flannery, 1994). Among patients diagnosed with a second primary 
lung cancer five or more years after breast cancer treatment, the risk of lung cancer 
increased linearly with radiation dose, 8.5% per Gy (95% CI: 3.1–23.3%; p < 0.001) 
(Grantzau, Thomsen, Væth, & Overgaard, 2014); the association was exaggerated for 
ever-smokers with an excess rate of 17.3% per Gray (95% CI: 4.5 – 54%; p < 0.005). A 
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dose-response relationship with lung cancer risk has also been reported for alkylating 
agents used in chemotherapy for Hodgkin lymphoma, after controlling for radiation 
exposure and tobacco smoking (Travis et al., 2002). 
Smoking can exacerbate the SPC risks associated with radiotherapy. In a nested 
case-control study of future non-breast cancer among 23,627 early breast cancer patients 
treated with radiotherapy, 91% of the cases (those who developed SPLC) were ever-
smokers versus only 40% of the controls (those who did not develop SPLC) (Grantzau et 
al., 2014). Increased lung cancer risk in those treated with radiation may be confounded 
by smoking status since it is related to both lung cancer risk and exposure to 
radiotherapy. Smoking-related comorbidities can make surgery a non-viable option, thus 
smokers may be more likely to be treated with radiation therapy alone than with 
potentially curative surgery. 
There is also evidence that radiotherapy can modify the effect of cigarette 
smoking on subsequent lung cancer risk. Kaufman and colleagues conducted a 
population-based nested case-control study among women with breast cancer and found 
that, compared to non-smokers who were not exposed to radiotherapy, odds ratio for 
SPLC were 5.9 (95% CI: 2.7 – 12.8) for ever-smokers who did not receive radiotherapy 
and 18.9 (95% CI: 7.9 to 45.4) for ever-smokers who received it. Radiotherapy did not 
increase the risk of SPLC in non-smoking women (OR = 0.6; CI: 0.2 – 2.4) (Kaufman, 
Jacobson, Hershman, Desai, & Neugut, 2008). 
2.2.2 Age 
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There is a marked increase in lung cancer incidence after age 60. The percentage of men 
in the United States who develop lung cancer in the following 10 years is 2.05 at age 60, 
compared to 0.71 at age 50 and the figures among women are 1.56 and 0.58, respectively, 
based on data from 2009 (Howlander et al., n.d.). Although not directly analogous, the 
most comparable figures for 2009 in Canada also show a considerable increase as 
follows: 2.3% of men aged 60-69 compared to 0.7% of men aged 50-59. The respective 
figures for Canadian women are 1.8% and 0.7%.  
Table 2.2 Probability (%) of developing lung cancer in next 10 years by age, United 
States and Canada, 2009 
United States   Canada 
Age Males Females Age Males Females 
50 0.71 0.58 50-59 0.7 0.7 
60 2.05 1.56 60-69 2.3 1.8 
 
Similarly, Tabuchi et al. reported marked increases in absolute risk of subsequent 
primary cancer (SPC) of any type among Japanese cancer survivors aged 60-69 compared 
to 50-59; this was the case for maximum follow-up lengths of both 5 (4.1% vs 2.7%) and 
10 years (8.6% vs 5.8%) (Tabuchi, Ito, Ioka, Miyashiro, & Tsukuma, 2012). A cut-point 
of 60 years of age was also used to distinguish between early vs. late onset of a family 
history of lung cancer in the LLP risk prediction model (Cassidy et al., 2008). 
2.3 Lung Cancer Screening 
Ideally, screening facilitates the detection of lung cancer at an early stage when treatment 
is most likely to be effective; currently, lung cancers are typically diagnosed at an 
advanced stage. The hazards associated with lung cancer screening include futile 
detection of small, aggressive tumours which have already spread or indolent disease 
which would never have led to advanced disease if ignored, complications from 
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diagnostic workup, the consequences of both false-positive and false-negative results, 
exposure to radiation and cost. However, the potential of decreased lung cancer mortality 
and improvement of quality of life can make screening worthwhile, provided that it is 
cost-effective enough to invest in (Wood et al., 2012). A systematic review of the harms 
and benefits of low-dosage computed tomography (LDCT) screening for lung cancer 
concluded that screening may be beneficial to those at high-risk but the potential harms 
and generalizability of results requires further investigation (Bach et al., 2012). 
Precise guidelines for lung cancer screening in the United States are provided by 
the United States Preventive Services Task Force (USPSTF). Annual lung screening with 
LDCT is recommended for those aged 55-80 years with at least 30 pack-years history of 
smoking, who are either currently smoking or have quit within the last 15 years. A person 
should not be screened if they have a substantially shortened life expectancy or are either 
unable or unwilling to have curative lung surgery and it should be discontinued if a 
person has not smoked for 15 years (Moyer, 2014). Medicare also has its 
recommendations for lung cancer screening since it reimburses those over age 65. The 
Center for Medicare and Medicaid Services considers those aged 55-77 with ≥ 30 pack 
year smoking histories and who have quit within 15 years to be eligible for lung cancer 
screening (Centers for Medicare & Medicaid Services, 2015).  
It has been shown that both the harms and benefits of LDCT screening are more 
favorable among those who have a higher risk of lung cancer. Among the participants of 
the NLST, the number of lung-cancer related deaths per person-years that were prevented 
by LDCT in comparison to chest radiography increased with lung cancer risk (Kovalchik 
et al., 2013).  
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2.4 Risk Prediction Models for Lung Cancer 
Risk prediction models are mathematical functions which use predictor variables 
(covariates) to estimate the absolute probability that a particular outcome will occur 
within a specific time period for an individual, given their predictor profile (Moons et al., 
2012). Predictors might include subject characteristics, examination results, or imaging 
results and so forth. Both independent (predictors) and dependent (outcome) variables 
may be continuous or categorical.  
In developing a multivariable risk prediction model, the most influential 
covariates are identified from a preselected set of candidate predictors. A modeling 
technique is then specified and used to determine how much of the variation in the 
outcome can be explained by the predictors. Relative weights are assigned to each 
predictor as a measure of the magnitude and direction of their relationship with the 
outcome. These are then combined to produce an overall risk score. 
Before model development begins, a number of issues must be addressed 
including: 
 Selection of relevant predictors 
 How to handle missing data 
 How to model each predictor  
 Strategy for inclusion of covariates 
 How to evaluate the performance of the model  
Several strategies exist for determining which covariates should be included a 
prediction model. Often a sequence of hypothesis tests is applied and predictors are 
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chosen on the basis of statistical significance. However, this approach confuses 
hypothesis testing with prediction modeling and can lead to the omission of useful 
predictors, thus selection based on effect estimates is preferable (Royston, Moons, 
Altman, & Vergouwe, 2009). Regression analyses may show statistically significant 
associations between risk factors and lung cancer but may fail to improve the predictive 
capacity of a model to any useful extent. The opposite is also true in that non-significant 
predictors may still improve prediction if included. Selecting predictors based on prior 
scientific knowledge is preferable to arbitrary inclusion of potentially useful factors. 
Models are sometimes built up from a constant and a single covariate (forward 
selection) but backwards elimination (initially including all potential predictors and 
sequentially removing the least influential ones) is often preferred since suppressor 
effects, that is, effects which only occur when another variable is held constant, can 
otherwise be missed (Field, 2009). Backwards elimination usually performs better than 
forward selection when some covariates are highly correlated (collinearity) and examines 
a full model fit which is the only method that provides accurate standard errors and p-
values (Harrell, 2001). 
The most widely used modeling technique for dichotomous outcomes is perhaps 
logistic regression (Weisburd & Britt, 2014). Logistic regression fits the data according to 
an S-shaped logistic curve which follows a linear model in the middle of its distribution 
but flattens as it as it approaches 0 or 1 such that the outcome is constrained to values 
between 0 and 1. This ensures that predictions cannot be outside the range of actual 
values of what we are trying to predict (the probability of a binary outcome). In OLS 
regression, the prediction of 𝑌 is represented by the following equation: 𝑌 = 𝑌0 +
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 𝛽1𝑋1 … 𝛽𝑛𝑋𝑛 which can yield values greater than 1 or less than 0. In logistic regression, 
rather than predicting 𝑌 itself, we predict the natural logarithm (ln) of the odds of the 
event occurring, also known as the logit of 𝑌. Mathematically, this model is represented 
as: 
𝑙𝑛 (
𝑃(𝑌 = 1)
1 − 𝑃(𝑌 = 1)
) = 𝑙𝑛 (
𝑃(𝑌 = 1)
𝑃(𝑌 = 0)
) =  𝛽1𝑋1 … 𝛽𝑛𝑋𝑛  
Regression coefficients (Bi) on the right hand side of the equation still represent the 
change in the dependent variable for every one unit increase in the independent (Xi) and 
can be exponentiated to produce odds ratios (ORs), i.e. the relative odds of the outcome 
occurring given a particular exposure compared to being unexposed (Szumilas, 2010). 
The estimates produced by logistic regression are based on maximum likelihood 
estimation (MLE) technique which attempt to maximize the probability that the 
regression estimates will follow a distribution similar to that of the observed data. This 
process attempts to improve on tentative mathematical solutions based on a likelihood 
function. This function measures the probability of the observed results given the current 
regression coefficients. Typically, logistic regression uses -2 times the natural logarithm 
of the likelihood function (-2LL). Successive iterations of models are compared until the 
change in likelihood function is negligible – the solutions have ‘converged’ (Weisburd & 
Britt, 2014). 
2.4.1 Model Performance 
Model performance refers to the quality of the predictions made from it. The overall 
predictive performance of a model can be assessed in a variety of ways, with the distance 
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between the predicted outcome and the actual outcome (𝑌 − ?̂?) playing a central role. 
These distances relate to the ‘goodness-of-fit’ of a model - better models have smaller 
distances. (Steyerberg et al., 2010). 
The amount of total variation in the outcome variable explained by the model (R2) 
is the most common overall fitness score for continuous outcomes (linear regression 
models) but for dichotomous outcomes, models are scored with the logarithm of 
predictors:  
𝑌 ∗ log(𝑝) + (𝑌 − 1) ∗ (log(1 − 𝑝)). 
R2 statistics cannot be calculated for models with binary outcomes as modeled 
using logistic regression models. Several pseudo-R2 s have been devised as analogous 
alternatives but none is equivalent and they can vary widely for the same data. Instead, 
measures based on the difference in -2 log likelihood between models are used 
(Steyerberg et al., 2010). Overall performance measures comprise two main 
characteristics, discrimination and calibration, both of which are usually evaluated 
individually. The Brier score, a measure of average prediction error, is also used to assess 
overall model performance. It is calculated by squaring the absolute difference between 
the observed and predicted probabilities for each individual and then taking the average 
of this across the sample (Brier, 1950). A lower Brier score indicates lower average error 
and thus better prediction and a Brier score of 0.25 represents random classification.  
2.4.1.1 Discrimination 
Discrimination refers to the accuracy with which a predictive model classifies those who 
experience the outcome and those who do not. Put simply, it is the probability that a 
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single randomly selected participant will be correctly classified by the model as either 
experiencing the outcome (being diagnosed with lung cancer in this case) or not. Several 
measures are available to assess this for a binary outcome. The area under the receiver 
operating characteristic (ROC) curve (AUC) statistic is the most common indicator of 
discrimination for general linear models. The statistic describes how well a model can 
rank order predicted values in order to separate those who experienced the outcome from 
those who did not. Since rank order is used, the statistic is not a function of the actual 
predicted probabilities and as such is insensitive to any distances between them. The 
AUC represents the probability that a positive observation (𝑌 = 1) will be ranked higher 
than a negative one (𝑌 = 0) (Fawcett, 2006). 
The AUC is represented graphically by plotting the true positive rate (sensitivity) 
against the false positive rate (1-specificity) (Steyerberg et al., 2010). The sensitivity and 
specificity are paired at all consecutive cut-offs points (the predicted probability for each 
observation). The (theoretical) maximum value of the AUC is 1.0, indicating perfect 
classification, whereas a value of 0.5 indicates the classifications are no better than 
random chance. An AUC of between 0.5 and 0.7 is considered by Hosmer and 
Lemeshow as poor discrimination, with an AUC of 0.7 to < 0.8 indicating acceptable 
discrimination, and an AUC of 0.8 to <0.9 representing excellent discrimination and 
anything higher to be outstanding discrimination (Hosmer et al., 2013).  
2.4.1.2 Calibration 
Calibration refers to the agreement between the probabilities of the outcome as estimated 
by the model versus the observed event probabilities (Steyerberg et al., 2010). Calibration 
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plots provide a graphical representation of this agreement, with predictions on the x-axis 
and observed outcomes on the y-axis. Perfect predictions lie on a 45-degree line 
(theoretically). For continuous outcomes, this basic scatter plot will suffice but for binary 
outcomes, the y-axis only contains the values 0 and 1, so smoothing techniques can be 
used to approximate the observed outcome probabilities, 𝑝(𝑌 = 1) in relation to the 
predicted probabilities using locally weighted linear regression algorithms (Steyerberg et 
al., 2010). The intercept (α) of a calibration plot indicates whether the predictions are 
systematically too high or too low (ideally, 𝛼 = 0) and the slope (β) should ideally be 
equal to 1, indicating perfect prediction. Numerical measures of calibration can include 
median and 90th percentile absolute error (differences between observed and predicted 
values) (Hyndman & Koehler, 2006) as well as a sub-component of the Brier score, the 
Spiegelhalter statistic. 
The correspondence between the predictions of a logistic regression model and 
observations or its ‘goodness-of-fit’ is often assessed by the Hosmer-Lemeshow test 
(Hosmer & Lemeshow, 1980). A cross-tabulation of observed and expected values is 
created, usually per decile of predicted probabilities by binary outcome status. However, 
the Hosmer-Lemeshow statistic has been criticized for several reasons (Desai, Bruce, 
Desai, & Druss, 2001; Hosmer, Hosmer, Le Cessie, & Lemeshow, 1997; Kramer & 
Zimmerman, 2007; Steyerberg, 2009; Vittinghoff, Glidden, Shiboski, & McCulloch, 
2011):  
 The standard binning of probabilities by decile is arbitrary and using a 
different number of groups, even 9 or 11 can completely change the result.  
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 The statistic does not possess considerable power to detect lack of 
calibration and does not adequately penalize overfitting.  
 Adding non-linear or interaction terms which ought to improve model fit 
may, paradoxically, result in lower p-values (a poorer result). 
 With a large enough sample size, statistical significance (a failed test) can 
be achieved even when observed and predicted probabilities closely agree. 
Overfitting is a situation in which a statistical model describes too much random 
error or noise rather than the underlying relationship and generally occurs when a model 
is overly complex, with too many predictors relative to the number of observations. In 
short, they fit the dataset used to estimate the parameters better than different data and 
generally have poor predictive performance in external or new or test data as a result. 
This can be problematic with large sample sizes where the statistical significance of 
relatively innocuous differences between observed and expected values can be 
misinterpreted as poor calibration when in reality this is expected to occur by chance. 
Overfitting can be corrected for using statistical resampling techniques such as the 
Quenouille-Tukey jackknife (Efron & Stein, 1981) and bootstrapping (Efron, 1979). 
Bootstrapping allows for repeated resampling of data to produce numerous alternate 
datasets of the same size as the original. A statistic can be re-calculated for each of these 
bootstrapped datasets and then averaged to produce bias-corrected estimates and 
confidence intervals. To help minimize the likelihood of overfitting, the number of 
outcome events per the number of predictors in the model should be at least 10 but 
preferably >50 (Steyerberg et al., 2010). 
2.4.2 Notable Lung Cancer Prediction Models 
  
37 
 
Relatively few models have been developed to estimate lung cancer risk. One of the 
earliest models, the Harvard Cancer Risk Index (Colditz et al., 2000), was based on 
literature reviews and general consensus. Key risk prediction models based on more 
reliable data were subsequently developed: the Bach model, (Bach et al., 2003) the Spitz 
model, (Spitz et al., 2008) and the Liverpool Lung Project (LLP) model (Cassidy et al., 
2008).  Smoking duration and occupational asbestos exposure are factors common to all 
three models. However, they differ in terms of other risk factors such as lung-related 
comorbidities (emphysema vs pneumonia), history of prior malignancies, and definition 
of family cancer history. A summary table of the characteristics of these models is 
available for ease of comparison (Etzel & Bach, 2011). 
The Bach model was developed using data from the β-Carotene and Retinol 
Efficacy Trial (CARET), a randomized controlled trial of β-Carotene and vitamin A 
supplements among 14,254 heavy smokers and 4,060 asbestos-exposed participants 
(Bach et al., 2003). Bach et al used Cox proportional hazards regression to develop 1-
year probability models for lung cancer diagnosis. The models contain the same 
variables: number of cigarettes per day, number of years smoked, number of years quit 
(among former smokers), age, sex, and exposure to asbestos. These 1-year models were 
run recursively 10 times to predict 10-year absolute lung cancer risk. Bach et al. 
estimated 10-year absolute risk "because it is probably in excess of the time it takes for 
lung cancer to progress from an undetectable size to an untreatable stage; consequently, it 
is a useful perspective from which to counsel patients about screening" (Bach et al., 
2003). 
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The Spitz model was based on 1,851 lung cancer cases matched with 2001 
controls according to age, sex, race and smoking status (never, former, current). Logistic 
regression was used to create separate models for each smoking status category and 
estimate the relative risk of developing lung cancer. Relative risks from these models 
were combined with age- and sex-specific incidence rates to present 1-year absolute lung 
cancer risk (Spitz et al., 2007). 
The LLP model was derived using data from 579 lung cancer cases and 1,157 
age-, sex- matched controls taken from a case-control study that was part of the Liverpool 
Lung Project. The cases were also frequency matched on smoking status so the impact of 
smoking could not be accurately assessed. Logistic regression models were used to 
estimate relative lung cancer risk. Case-control data and regional age-standardized lung 
cancer incidence rates were combined to present 5-year absolute lung cancer risk 
(Cassidy et al., 2008). Prior to the PLCO Trial, lung cancer risk prediction models were 
limited in terms of the number of possible predictors, and demonstrated low predictive 
performance (Tammemagi et al., 2011). Data from the PLCO trial allowed improved 
models to be developed using a wider range of risk factors, a prospective study design, 
and evaluation of non-linear effects. Factors comprised age, socioeconomic status (using 
education as a proxy), BMI, family history of lung cancer, COPD, recent chest x-ray, 
smoking status (never, former, or current), pack-years smoked, and smoking duration 
were used to predict the probability of lung cancer diagnosis during the ongoing follow-
up in both the general population (model 1) and a sub-cohort of ever-smokers (n=38,254) 
(model 2). Model 2 also incorporated smoking quit-time (the time in years since the 
person has permanently quit smoking). Both models demonstrated high discrimination. 
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The AUC for models 1 and 2 were 0.857 and 0.805 respectively and the values for the 
calibration slopes were 0.987 and 0.784, respectively (Tammemagi et al., 2011).  
The 2011 lung cancer risk prediction model based on the PLCO trial data was 
later modified to facilitate compatibility with data from the NLST. The resultant logistic 
regression model predicting the probability of lung cancer diagnosis during the 6-year 
study period (PLCOM2012) demonstrated an AUC of 0.803 in the development dataset 
(PLCO control-group smokers) and 0.797 in the validation dataset (PLCO intervention-
group smokers). Mean absolute error and 90th percentile absolute error were 0.009 and 
0.042, respectively. (Tammemagi et al., 2013). Predictors included: age, race/ethnicity, 
education level (a surrogate for socioeconomic circumstance), BMI, COPD, personal 
history of cancer, family history of lung cancer, smoking status, smoking intensity, 
smoking duration, and smoking quit time. PLCO M2012 was later modified to produce a 
model applicable to never-smokers as well as ever-smokers (PLCOall2014) (Tammemagi 
et al., 2014). Since the current analysis is based on data from the PLCO and NLST, it 
makes the most sense to use the use the models developed using PLCO data as a basis for 
potential improvement. These models have shown superior performance compared to 
previous efforts, they have been thoroughly described and validated, and are well 
accepted by the research community. 
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CHAPTER 3: METHODOLOGY 
3.1 Introduction 
The design of the study and its methodology is summarized in this chapter including 
acquisition of the data, specific measures investigated and the steps taken to organize and 
utilize the data as appropriate. Details of the specific analytic strategies employed to 
address the research questions proposed in the first chapter conclude this section. 
3.2 Design and Context of the Original Studies 
This research is derived from two multi-center randomized controlled trials conducted in 
the United States, details of which are provided in the following sections. These original 
studies collected a comprehensive array of patient characteristics and extensive data with 
particular respect to risk factors for lung cancer. Additional variables were synthesized 
from the available data as part of this project in order to better assess the effects of having 
a previous history of cancer.   
3.2.1. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial 
The PLCO randomized controlled trial investigated the effect of screening for lung 
cancer using chest radiography versus usual care with respect to lung cancer specific 
mortality (Oken et al., 2011). The main outcome measure was mortality from lung 
cancer, with lung cancer incidence, complications associated with diagnostic procedures 
and all-cause mortality as secondary endpoints. A detailed description of the design and 
operation of the PLCO can be found elsewhere (Prorok et al., 2000) but a brief summary 
is presented here. 
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3.2.1.1 Recruitment and Randomization (PLCO) 
Enrollment began in 1993 at 10 screening centers in the United States and continued until 
2001. A total of 154,942 participants were recruited by mass mailing, of which 154,901 
were assigned to either the intervention or usual care group using block randomization, 
stratifying them by screening center, sex and age. Of those randomized, 77,445 received 
usual care and 77,456 in the intervention arm were screened with annual posterior-
anterior view chest X-rays, 67,038 of whom received an initial screening at baseline 
followed by three additional annual screenings (except for never-smokers randomized 
after April 1995 who were not offered the third screen) (Oken et al., 2011). All 
participants in the PLCO trial signed informed consent documentation approved by both 
the National Cancer Institute and their local institutional review board (Oken et al., 
2011).  
3.2.1.2 Eligibility Criteria (PLCO) 
Eligibility was restricted to patients not participating in other cancer screening or primary 
prevention trial, aged between 55 and 74 years. Among other criteria, those who had been 
previously diagnosed with prostate, lung, colorectal or ovarian cancer at any time, or 
receiving treatment for any cancer other than basal cell or squamous cell skin cancer were 
excluded (Oken et al., 2005). Some survivors of prostate, lung and colorectal cancer 
remained in the dataset however, so it was possible to investigate the effects of these 
cancer types to some extent in the current study.  
3.2.1.3 Data Collection (PLCO) 
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Upon entry to the study, participants completed a self-administered baseline 
questionnaire comprising questions regarding their sociodemographic characteristics 
(age, race/ethnicity, sex, marital status, education), family history of lung cancer, 
personal medical history, cigarette smoking history and cancer screening history (Oken et 
al., 2011). 
Cancers diagnosed at any site and all deaths were ascertained by a mailed annual 
update questionnaire. Repeat questionnaires were sent if initial ones were not returned, 
else the participant was contacted by telephone. Periodic checks against the National 
Death Index complimented the follow-up (Oken et al., 2011). All deaths potentially 
related to a PLCO cancer were assessed by reviewers blinded to the trial group. 
Lung cancer-specific deaths were defined as those whose underlying cause was 
lung cancer itself or a result of treatment for it. Among those in the intervention group, 
cancers were defined as screening-detected if they were diagnosed within a 9 month 
period after a positive screen result (or the diagnostic evaluation linked to it). Non-
screening detected cancers were classified as interval if they occurred up to one year after 
the most recent scheduled screening or post-screening if they occurred more than one 
year after the final screening (Oken et al., 2011).  
3.2.2 The National Lung Screening Trial 
The NLST is a multicenter randomized controlled trial (RCT) designed to compare two 
methods of screening for lung cancer: low-dose computed tomography (LDCT) and chest 
radiography. The effects of these techniques on lung cancer mortality rates among current 
and former smokers were assessed. The primary endpoint of the study was lung cancer 
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mortality, and secondary endpoints included lung cancer incidence, treatment or 
screening related morbidity, quality of life and cost-effectiveness (National Lung 
Screening Trial Research Team, 2011). The design of the NLST has been described 
previously (National Lung Screening Trial Research Team, 2011) but a summary is 
presented here. Initiated in 2002, the NLST is a study funded by the U.S. National Cancer 
Institute (NCI), Division of Cancer Prevention and is based on a smaller-scale pilot study 
known as the Lung Screening Study. The NLST was jointly conducted by Lung 
Screening Study (LSS) screening centres (mostly PLCO centres), and the American 
College of Radiology Imaging Network (ACRIN), funded by the NCI Division of Cancer 
Treatment and Diagnosis. The study protocols and data collection forms used by LSS and 
ACRIN were harmonized (National Lung Screening Trial Research Team, 2011).  
3.2.2.1 Recruitment and Randomization (NLST) 
Thirty-three medical centres throughout the United States took part in the NLST 
(Clinicaltrials.gov, NCT 00047385). Participants were recruited using a variety of 
strategies including direct mailings and use of mass media with support from both the 
NCI’s Cancer Information Service and the American Cancer Society. The Census 
Department’s Tobacco Use Supplement of the Continuing Population Survey for 2002-
2004 was used to ascertain whether the study population was representative of those 
eligible to participate from the whole US population. Enrolment was completed between 
2002 and 2004. A total of 53,452 participants were included. Targeted recruitment 
strategies were used to enrol minority populations (Aberle et al., 2010). Participants were 
randomly assigned to either the CT or chest radiograph arm, stratified by site, sex and 5-
year age group using a block size of six or eight (Aberle et al., 2011). The study was 
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conducted after approval by an institutional review board at each institution. Each 
participant provided written informed consent (Aberle et al., 2010). 
3.2.2.2. Eligibility Criteria (NLST) 
The NLST required participants to meet the following basic criteria (among others 
described in further detail by Aberle et al. (2011))  in order to be eligible to take part in 
the trial: 
 Aged between 55 – 74 years 
 Have a minimum of 30 pack-years history of cigarette smoking 
 Former smokers must have quit within 15 years of randomization 
 No history of lung cancer 
 No participation in other cancer screening trial or cancer prevention study 
 No evidence of any cancer other than non-melanoma skin cancer or 
carcinoma in situ within the preceding 5 years 
 Signed informed consent form 
Those who still smoked cigarettes regularly were defined as current smokers. Some lung 
cancer survivors remained in the dataset and were included in the current analysis. 
3.2.2.3 Data Collection (NLST) 
Low-dose helical CT scans were conducted using NLST-approved equipment according 
to a protocol appropriate at the time of the trial. The obtained LDCT images were 
electronically transmitted to ACRIN- or LSS-maintained central repositories (National 
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Lung Screening Trial Research Team, 2011). These scans were interpreted by NLST-
approved radiologists.  
NLST-certified chest radiographic machines were used to collect X-ray images. 
NLST-ACRIN images were permanently archived at ACRIN headquarters and NLST-
LSS images at the screening centres. Protocol requirements for chest radiograph 
interpretation were identical to those for used for interpreting LDCT images (National 
Lung Screening Trial Research Team, 2011). 
Data on patient characteristics were collected using epidemiological 
questionnaires upon study entry (National Lung Screening Trial Research Team, 2011). 
Each person was offered three lung cancer screenings – one at baseline and two annual 
screenings thereafter. LDCT images in the NLST were assessed for the presence of lung 
nodules, masses or other abnormalities suspicious for lung cancer (positive suspicious 
results) as well as other findings of potential clinical relevance. Morphological features 
were recorded for all non-calcified nodules and masses with a minimum diameter of 
4mm (National Lung Screening Trial Research Team, 2011). 
The datasets from the PLCO and NLST trials were harmonized to the extent 
possible, that is, common information collected on the participants of both trials so that 
associations based on these factors could be analyzed using a far greater sample size. 
This was done prior to this study by Information Management Systems, Inc. (IMS) on 
behalf of the NCI.  
3.3 Analytical Strategy 
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All statistical analyses for the current study were performed using the Stata software 
package (StataCorp. 2012. Stata Statistical Software: Release 13.1. College Station, TX: 
StataCorp LP.). Prior to analysis, some existing variables were modified and several new 
variables were created. The variables representing the age and BMI of the participant 
were centered to the mean (mean subtracted from the value), rounded to the nearest 
integer (62 years and 27 kg/m2, respectively) in order to make the regression coefficients 
for those variables more straightforward to interpret. Data cleaning consisted of looking 
for outliers and handling them as appropriate. Missing values had already been defined as 
such in the dataset by IMS. 
 Descriptive statistics for the risk factors analyzed consisted of calculating the 
mean and standard deviation for continuous variables and frequency and percentage for 
categorical ones. These statistics were stratified by trial (PLCO vs. NLST) and outcome 
status (lung cancer diagnosed during follow-up or no lung cancer). To test for statistically 
significant differences across each pair of strata, two-sample independent t-tests or Mann-
Whitney U were performed for continuous variables as appropriate, depending on 
whether normality could be assumed. Chi-squared tests were conducted for categorical 
variables or Fisher’s exact tests in cases where any expected cell count was less than 5.  
Logistic regression models were used to assess the association of each variable 
under investigation with subsequent primary lung cancer (SPLC) before and after 
adjustment. This approach was chosen because the outcome is dichotomous and logistic 
regression would facilitate direct comparisons with established models. Also, individual-
level predicted values are straightforward to compute from such models. Follow-up was 
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truncated at six years to further ensure comparability with previous models as well as 
between the participants of the PLCO and NLST. 
All univariate and multivariable analyses were conducted for PLCO and NLST 
participants separately followed by re-testing any notable associations with harmonized 
data, where appropriate, i.e., heterogeneity of effects did not exist. The associations of all 
study variables with lung cancer were first assessed in univariate analysis and then 
adjusted for the covariates in the PLCOall2014  (Tammemagi et al., 2014)): age, 
race/ethnicity, education, BMI, COPD, family history of lung cancer, smoking status, 
smoking intensity, duration and quit time. Personal history of cancer was omitted since 
the variables being tested are variants of the same factor. Ordinal variables were assessed 
for evidence of a dose-response pattern where applicable. Ordinal variables were treated 
as continuous if it was sensible to do so, in order to minimize degrees of freedom in the 
model.  
Multivariable fractional polynomials (MFPs) were used to determine whether any 
of the predictors from the PLCOall2014 should be modeled using non-linear 
transformations and which transformations were most suitable. Using this approach, the 
best power transformation for a variable 𝑥 (𝑥𝑝) is found where the power p is chosen 
from the following set of candidates {-2, -1, -0.5, 0, 0.5, 1, 2, 3} (Royston & Altman, 
1994). It has been acknowledged by others that low order polynomials (such as quadratic 
or cubic) can model only a few possible curve shapes and high order ones fit the data 
more closely but often do so poorly for extreme values of x. This restricted set of 
fractional polynomials have been shown to have extensive flexibility and since iterative 
algorithms for testing possible candidates are implanted in most statistical software 
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packages, this approach is simple to carry out. Transformations are straightforward to fit 
into standard regression models (Royston & Altman, 1994). Suggested transformations 
were used in place of the original linear terms when conducting adjusted analyses. The –
mfp- command in Stata was used to conduct the MFP analysis. The number of degrees of 
freedom for the transformations was capped at 2 in order to exclude non-linear 
relationships that were implausible - this limits the complexity of the curve representing 
the relationship between the continuous predictor and the probability of the outcome (i.e. 
the number of times it can change direction). For example, if the probability of lung 
cancer increases sharply beyond a certain smoking intensity threshold, the gradient 
should be allowed to become steeper to reflect this but it does not make biological sense 
that the curve should be allowed to become inverted at even higher smoking intensities. 
Since the influence of the covariates from PLCOall2014 was established prior to the 
study, conclusions were only drawn from adjusted analyses. Effects observed in 
unadjusted analyses may be attributable to known factors hence associations seen after 
accounting for these influences are more important. Additionally, all associations were 
also adjusted for clustered sampling based on screening center, in order to control for 
both known and unknown differences between centers such as the proficiency of the 
medical staff, access to technology, sociodemographics of their patients or even localized 
environmental factors which could be carcinogenic, all of which could introduce bias into 
the analyses. This adjustment increases the robustness of the standard errors. 
Personal history of cancer 
1. Type of cancer 
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Are any specific types of previous cancers strong independent predictors of subsequent 
lung cancer?  
The dataset contained variables that show whether or not the participant reported having 
previously been diagnosed with cancer (0=no, 1=yes) at the following anatomical sites: 
Breast 
Digestive: Colorectal, esophageal, pancreatic, stomach 
Endocrine: Thyroid 
Genitorurinary: Bladder (including transitional cell), kidney, prostate, testicular 
Gynecologic: Cervical, uterine 
Head and neck: Laryngeal, nasopharyngeal, oral 
Hematologic: Hodgkin lymphoma, non-Hodgkin lymphoma 
Lung 
The variables for Hodgkin lymphoma, non-Hodgkin lymphoma, prostate, 
testicular and uterine were created manually based on data provided by the PLCO 
participants for up to four previous cancers. Nasal, oral, pharyngeal and transitional cell 
cancers were reported for NLST participants only, but the PLCO did contain data on 
previous cancers classified as ‘nasopharyngeal’ so nasal and pharyngeal cancers were 
combined for the NLST participants such that one variable would be applicable to those 
in either trial. Since transitional cell cancers are a subset of bladder cancers, these were 
combined into a single variable. The variable denoting previous COPD diagnosis was 
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modified to also include diagnosis of emphysema and chronic bronchitis since COPD 
encompasses these conditions. 
Logistic regression models were used to quantify the association of each of these 
variables with lung cancer before and after adjustment and the sample was restricted to 
males or females only when studying the effects of sex-specific cancer types. 
Associations were evaluated separately among PLCO and NLST participants. When 
testing the associations for each previous cancer type, some models would not converge 
due to complete separation. In these instances, to circumvent the problem, a single 
participant who developed lung cancer during follow-up was treated as having survived 
the type of cancer being tested, even though they did not.  
2. Number of previous cancers 
Is the number of previous cancers with which a person has been diagnosed an important 
predictor of future lung cancer? 
A score based on the sum of all dichotomous (0/1) variables representing each 
specific cancer type was generated for all participants and coded as (0, 1, 2+). Only 9 
people reported more than two different previous cancer types, hence grouping them 
together to form the 2+ category. Further questions specific to PLCO participants 
gathered information regarding up to four previous cancers. This information was 
incorporated into the ‘number of previous cancers’ variable so as to capture as much data 
as possible. After conducting adjusted analyses for this variable, post-estimation Wald 
tests were performed to determine whether any difference between the 1 and 2+ 
categories was statistically significant for either the PLCO or NLST sub-groups. 
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3. Age at cancer diagnosis  
Is being diagnosed with cancer before age 60 associated with future lung cancer risk 
more strongly than at 60 or older? 
PLCO participants reported their age at diagnosis for up to four cancers. In both 
trials, age at diagnosis was also recorded for each of the specific previous cancer types 
listed in Q1.    
Age at diagnosis was categorized in ordinal form as follows: no previous cancer, previous 
cancer(s) diagnosed at 60 years or over, and at least one cancer diagnosis before age 60, 
respectively). A post-estimation Wald test was performed to determine whether the any 
difference between the 60+ and <60 categories was statistically significant.  
 
Do any of these associations lead to improved prediction models? 
Variables for which positive effect sizes of at least 15% (i.e. ORs ≥ 1.15) were observed 
after adjustment were considered for inclusion in multivariate modeling. Only cancers 
that showed strong effects in the participants of both trials (where possible) were 
considered as it did not make sense to include associations that were inconsistent. 
Although ultimately down to a priori knowledge and judgment, the threshold was chosen 
because it is large enough to be clinically relevant and far enough away from the null (no 
effect) so as to be unlikely due to residual confounding, but sensitive enough so that 
important effects were unlikely to be ignored. A dichotomous summary variable was 
created to indicate a previous diagnosis of any of these previous cancer types with 
elevated risks for inclusion in later models. This was done in order to minimize the 
degrees of freedom in the model and maximize the predictive utility of the information. 
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Two further binary personal history of cancer variables were created. The first 
represented a history of smoking-related cancers since tobacco use likely increases a 
tendency towards multiple cancers at such sites:  lung, nasopharyngeal, oral, laryngeal, 
pancreatic, esophageal, kidney, stomach, bladder, cervical or colorectal (American 
Cancer Society, 2014)) and the second represented a history of head and neck cancers as 
these are the most strongly associated with SPLC according to previous studies. All three 
of these dichotomous variables were considered as candidates to replace the original 
‘personal history of any cancer’ variable in the PLCOall2014 model. Additionally, 
interaction effects between the best performing personal history of cancer variable and 
age at previous cancer diagnosis (60+/<60 years) was evaluated. Other interaction effects 
based on a priori knowledge included sex-race/ethnicity, sex-smoking intensity and sex-
smoking duration, but none of these interaction terms were found to be significant so 
were not carried forward to more complex models. Ideally, interactions with age of 
previous cancer diagnosis should have been tested for each specific previous cancer site 
but this would have made the analysis somewhat verbose and statistical power was 
minimal so priority was given to testing the interaction with only the original summary 
term. 
Further models were then built by including all variables that improved 
discrimination alongside the PLCOall2014 covariates, and then those variables which 
increased discrimination by negligible amounts were successively removed to produce 
the most parsimonious model.  
Predicted probabilities were calculated using the formula: 
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𝑃(𝑌 = 1) =
1
1 + 𝑒−(𝛽0+𝛽1𝑋1+⋯𝛽𝑛 𝑋𝑛)
  
The model error was calculated as the absolute difference between observed 
probabilities and those predicted by the model. Calibration of the final model was 
assessed based on median and 90th percentile absolute error and the p-value of the 
Spiegelhalter’s z-statistic which is provided by Stata when computing the Brier score; 
this statistic tests the extent to which an individual Brier component is extreme, with a 
larger p-value (> 0.05) indicating better prediction (Spiegelhalter, 1986).  
Bootstrapping techniques were used to produce bias-corrected confidence 
intervals for both the AUC and Brier scores; in each case, 1000 replications were used, 
which is generally considered to be a reasonable number for such estimates (Duval, 
1993); internal validity was gauged based on the width of these confidence intervals. 
The amount of missing data was assessed by comparing the number of 
observations used in the estimation of the final model to the total number available for 
that analysis. If more than 10% of the participants were excluded, multiple imputation of 
missing data was considered in order to maximize the sample size used in estimation. 
Finally, the number of events in the sample will be divided by the number of predictors to 
ensure that the ratio between the two is sufficient to minimize overfit (> 50).  
3.4 Modeling Assumptions 
Unlike linear regression, binary logistic regression does not require a linear relationship 
between predictors and the outcome variable and the independent variables do not need 
to be normally distributed. Homoscedasticity of residuals is not required and variances do 
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not need to be equal across all values or levels of the predictors. Levels of measurement 
for the predictors are not limited to interval or ratio only. However, assumptions that do 
apply include the following (Menard, 2002; Pregibon, 1981; Tabachnick & Fidell, 2007): 
 The model is fitted correctly, meaning that no important variables are omitted and 
no extraneous variables are included. The inclusion of all predictors established in 
previous models as well as using a backwards selection method for new 
covariates should ensure that this is the case. Misspecification of the logistic 
function can be tested using the -linktest- post-estimation command in Stata. The 
specification link test is based on the principle that if a model is properly 
specified, additional predictors should only achieve statistical significance by 
chance. Linktest rebuilds the model using the linear predicted value (_hat) and the 
squared form of this value (_hatsq) as predictors. If the model is properly 
specified, _hatsq should not be statistically significant. If it is so, this may suggest 
that relevant predictors are omitted or the logit of the outcome is not a linear 
combination of the predictors and thus logit function is not the correct approach to 
use. Suggested transformations from the MFP analysis will ensure that non-linear 
relationships are modeled appropriately. 
 Graphical plots of the residuals from the model against the predicted values can 
be an effective way to check whether the level of measurement error for the 
predictors is problematic. Standardized Pearson residuals represent the relative 
deviation between observed and fitted values. The deviance residual measures 
discrepancy between the limits of the observed and fitted likelihood functions, 
analogous to the raw residual in OLS regression. Finally, the Pregibon leverage 
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statistic measures the influence of each observation which is useful when deciding 
whether to remove a problematic observation from the model. Each of these 
statistics will be plotted against the predicted values in order to assess this 
assumption. 
 The observations are independent, that is, the data from one participant should not 
depend on that of another or be from any dependent sampling design.  
 The predictors should be independent of one another, that is, no strong 
multicollinearity should be present. Centering variables can help reduce 
collinearity and problems with collinearity will be checked with variance inflation 
factor (VIF) statistics. Any strongly collinear variables will either be combined if 
possible or removed from the model as appropriate.  
 The independent variables are not linear combinations of one another. If this is the 
case for a predictor, Stata will automatically drop the variable from the model 
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CHAPTER 4: RESULTS 
Descriptive statistics for the study participants are presented separately for each screening 
trial in Tables 4.1 and 4.2. The former describes factors included in the PLCOall2014 
model, while the latter summarizes characteristics central to this thesis project. Results 
from the current analyses is described below. Results for PLCO and NLST participants 
are provided separately. Both unadjusted and adjusted results are presented in the 
summary tables, however only the latter will be discussed here given that this thesis is 
concerned with associations that persist after accounting for pre-established risk factors. 
The written summary is presented in the following manner: 
 Comparisons of participant characteristics first between screening trials based on 
crude estimations using the data from Tables 4.1 and 4.2. 
 Assessment of the impact of participant characteristics on cumulative lung cancer 
incidence.  
 Key study findings (Tables 4.3 – 4.9) summarized separately by research question 
and discussed firstly among PLCO participants and then for those in the NLST as 
appropriate. 
 Evaluation of whether assumptions applicable to the modelling procedures were 
met.  
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Abbreviations: BMI: Body mass index; CI: Confidence interval; COPD: Chronic obstructive pulmonary disease; N: Number; NLST: National Lung Screening Trial; PLCO: Prostate, Lung, Colorectal and Ovarian 
Cancer Screening Trial. 
* Percentages for ‘all’ are out of the total N for that column. Percentages may not add up to 100% due to missing data which is not shown here. 
† P-value for two sample t-test/Mann Whitney U test or Chi-sq./ Fisher’s exact test (PLCO vs. NLST for the corresponding variable). 
‡ P-value for two sample t-test/Mann Whitney U test or Chi-sq./ Fisher’s exact test (the difference in cumulative incidence between screening trials for that row).  
§ Percentages are row percentages, i.e. the percentages of participants for that row who developed lung cancer during follow-up.   
║ Diagnosis of COPD encompasses diagnoses of emphysema or chronic bronchitis; ¶ among ever-smokers; ** among former smokers. 
 
 
   
 
 Screening Trial Developed Lung Cancer During Follow-up 
 Harmonized 
(N = 208,352) 
PLCO  
(N = 154,900) 
NLST  
(N = 53,452) 
 PLCO  
(n =  1,636) 
NLST  
(n =  1,925) 
 
 N (%)* / Mean (SD) N (%)* / Mean 
(SD) 
N (%)* / Mean (SD) P-value† N (%)§ / Mean (SD) N (%)§ / Mean (SD) P-value‡ 
Age 62.3 (5.3) 62.6 (5.4) 61.4 (5.0) <.001 64.7 (5.3) 63.7 (5.3) <.001 
Sex    <.001    
Male 108,214 (51.9%) 76,684 (49.5%) 31,530 (59.0%)  990 (1.3%) 1,147 (3.6%) <.001 
Female 100, 138 (48.1%) 78,216 (50.5%) 21,922 (41.0%)  646 (0.8%) 778 (3.6%) <.001 
Race/ethnicity    <.001    
White 180, 484 (86.6%) 132,582 (85.6%) 47,902 (89.6%)  1,377 (1.0%) 1,739 (3.6%) <.001 
Black 10,069 (4.8%) 7,708 (4.9%) 2,361 (4.4%)  128 (1.7%) 98 (4.2%) <.001 
Hispanic 3,480 (1.7%) 2,818 (1.8%) 662 (1.2%)  20 (0.7%) 11 (1.7%) .034 
Asian 6,671 (3.2%) 5,576 (3.6%) 1,095 (2.1%)  32 (0.6%) 32 (2.9%) <.001 
Native Americans 579 (0.3%) 389 (0.3%) 190 (0.4%)  5 (1.3%) 9 (4.7%) .018 
Pacific Islanders 1,028 (0.5%) 835 (0.5%) 193 (0.4%)  10 (1.2%) 5 (2.6%) .176 
Unknown 6,041 (2.9%) 4,992 (3.2%) 1,049 (2.0%)  64 (1.3%) 31 (3.0%) <.001 
Education level    <.001    
Less than high school 14,330 (7.1%) 11,081 (7.2%) 3,249 (6.1%)  229 (2.1%) 172 (5.3%) <.001 
High school graduate 47,106 (23.3%) 34,394 (22.2%) 12,712 (23.8%)  432 (1.3%) 545 (4.3%) <.001 
Post high school training 26,261 (13.0%) 18,827 (12.2%) 7,434 (13.9%)  197 (1.1%) 285 (3.8%) <.001 
Some college 44,970 (22.2%) 32,693 (21.1%) 12,277 (23.0%)  348 (1.1%) 427 (3.5%) <.001 
College graduate 34,290 (16.9%) 25,344 (16.4%) 8,946 (16.8%)  200 (0.8%) 247 (2.8%) <.001 
Postgraduate 34, 830 (17.2%) 27,230 (17.6%) 7,600 (14.2%)  160 (0.6%) 203 (2.7%) <.001 
Other 966 (0.5%) 0 966 (1.8%)  64 (1.3%) 31 (3.2%) <.001 
Family history of lung cancer                                  27,532 (13.2%) 15,911 (10.3%) 11,621 (21.7%) <.001 284 (1.8%) 497 (4.3%) <.001 
No 169,726 (81.5%) 128,786 (83.1%) 40,940 (76.6%)  1,195 (0.9%) 1,386 (3.4%) <.001 
Body mass index, Kg/m2  27.5 (5.0) 27.3 (4.9) 28.0 (5.1) <.001 26.5 (4.4) 26.9 (4.7) .002 
Diagnosed with COPD║                           19,149 (9.2%) 9,823 (6.3%) 9,326 (17.5%) <.001 297 (3.0%) 517 (5.5%) <.001 
No                                      183,020 (87.8%) 139,089 (89.8%) 43,931 (82.2%)  1,258 (0.9%) 1,399 (3.2%) <.001 
Cigarette smoking status    <.001    
Never 69,183 (33.2%) 69,183 (44.7%) 0  110 (0.2%) 0  
Former 92,383 (44.3%) 64,691 (41.8%) 27,692 (51.8%)  807 (1.3%) 766 (2.8%) <.001 
Current 41,817 (20.1%)   16,057 (10.4%) 25,760 (48.2%)  655 (4.1%) 1,159 (4.5%) .041 
Smoking intensity, cigarettes/day ¶ 26.2 (13.6) 24.7 (14.6) 28.4 (11.5) <.001 29.9 (15.3) 29.6 (11.7) .447 
Smoking duration, years ¶ 32.6 (13.1) 27.7 (13.8) 39.8 (7.3) <.001 40.0 (10.7) 44.2 (7.0) <.001 
Smoking quit time, years ** 16.3 (12.0) 20.2 (12.0) 7.3 (4.8) <.001 12.5 (10.6) 6.6 (4.8) <.001 
Table 4.1 - Sample characteristics (variables used in PLCOall2014) for PLCO (N=154,900) and NLST (N=53,452) participants 
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Table 4.2 - Personal cancer history characteristics for study participants (N=208,352) by trial and lung cancer diagnosis 
 
 
 
 
 
 
 Screening Trial Developed Lung Cancer During Follow-up 
Personal cancer history variable 
Combined 
(N = 208,352) 
PLCO 
(N = 154,900) 
NLST 
(N = 53,452) 
 PLCO 
(n = 3,592) 
NLST  
(n = 2,058) 
 
 N (%)* N (%)* N (%)* P-value† N (%)§ N (%)§ P-value‡ 
Personal history of any cancer                9,205 (4.4%) 6,897 (4.5%) 2,308 (4.3%) .007 112 (1.6%) 126 (5.5%) <.001 
No                                                         194,193 (93.2%) 143,049 (92.4%) 51,144 (95.7%)  1,460 (1.0%) 1,799 (3.5%) <.001 
Number of previous cancers      .001    
1 8,699 (4.2%) 6,491 (4.2%) 2,208 (4.1%)  105 (1.6%) 120 (5.4%) <.001 
2+ 506 (0.2%) 406 (0.3%) 100 (0.2%)  7 (1.7%) 6 (6.0%) .027 
Previous cancer age category    <.001    
60+ 1,925 (0.9%) 1,606 (1.0%) 319 (0.6%)  31 (1.9%) 36 (11.3%) <.001 
< 60 7,088 (3.4%) 5,123 (3.3%) 1,965 (3.7%)  77 (1.5%) 86 (4.4%) <.001 
Breast║ 3,441 (3.4%) 2,702 (3.5%) 739 (3.4%) .617 29 (1.1%) 39 (5.3%) <.001 
No     617 (0.8%) 735 (3.5%) <.001 
Digestive        
Colorectal                              254 (0.1%) 24 (<0.1%) 230 (0.4%) <.001 0 9 (3.9%) 1.00 
No     1,636 (1.1%) 1,907 (3.6%) <.001 
Esophageal                            48 (<0.1%) 28 (<0.1%) 20 (<0.1%) .011 0 1 (5.0%) .417 
No     1,636 (1.1%) 1,915 (3.6%) <.001 
Pancreatic                             25 (<0.1%) 18 (<0.1%) 7 (<0.1%) .782 0 0  
No     1,636 (1.1%) 1,916 (3.6%) <.001 
Stomach                                 82 (<0.1%) 55 (<0.1%) 27 (0.1%) .128 0 1 (3.7%) .329 
No     1,636 (1.1%) 1,915 (3.6%) <.001 
Endocrine        
Thyroid                                425 (0.2%) 342 (0.2%) 83 (0.2%) .004 1 (0.3%) 3 (3.6%) .025 
No     1,635 (1.1%) 1,913 (3.6%) <.001 
Genitourinary        
Bladder                                590 (0.3%) 323 (0.2%) 267 (0.5%) <.001 19 (7.1%) 6 (1.9%) <.001 
No     1,906 (3.6%) 1,630 (1.1%) .001 
Kidney                                  282 (0.1%) 214 (0.1%) 68 (0.1%) .571 3 (1.4%) 4 (5.9%) .060 
No     1,633 (1.1%) 1,912 (3.6%) <.001 
Prostate¶                            35 (<0.1%) 35 (<0.1%) N/A  1 (2.9%) N/A  
No     989 (1.3%) N/A  
Testicular¶                          78 (0.1%) 78 (0.1%) N/A  0 N/A  
No     990 (1.3%) N/A  
Gynecologic║        
Cervical                               1,365 (1.4%) 600 (0.8%) 765 (3.5%) <.001 10 (1.7%) 30 (3.9%) .014 
No     636 (0.8%) 744 (3.5%) <.001 
Uterine                               532 (0.7%) 532 (0.7%) N/A  11 (2.1%) N/A  
No     635 (0.8%) N/A  
Head and neck        
Laryngeal                             138 (0.1%) 92 (0.1%) 46 (0.1%) .037 4 (4.4%) 2 (4.4%) .654 
No     1,632 (1.1%) 1,914 (3.6%) <.001 
Nasopharyngeal                 41 (<0.1%) 12 (<0.1%) 29 (0.1%) <.001 1 (8.3%) 2 (6.9%) .872 
No     1,635 (1.1%) 1,923 (3.6%) <.001 
Oral                                      103 (0.1%) N/A 103 (0.2%)  N/A 13 (12.6%)  
No     N/A 1,903 (3.6%)  
Hematologic        
Hodgkin lymphoma           73 (<0.1%) 73 (0.1%) N/A  1 (1.4%) N/A  
No     1,635 (1.1%) N/A  
Non-Hodgkin lymphoma   215 (0.1%) 215 (0.1%) N/A  4 (1.9%) N/A  
No     1,632 (1.1%) N/A  
Lung                                                   27 (<0.1%) 7 (<0.1%) 20 (<0.1%) <.001 2 (28.6%) 10 (50.0%) .326 
No     1,634 (1.1%) 1,906 (3.6%) <.001 
Abbreviations: BMI: Body mass index; CI: Confidence interval; COPD: Chronic obstructive pulmonary disease; N: Number; N/A Not present in dataset for participants of 
that screening trial; NLST: National Lung Screening Trial; PLCO: Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. 
* Percentages for ‘all’ are out of the total N for that column. Percentages may not add up to 100% due to missing data which are not shown here.  
† P-value for two sample t-test/Mann Whitney U test or Chi-sq. / Fisher’s exact test (PLCO vs. NLST for the corresponding variable). 
‡ P-value for two sample t-test/Mann Whitney U test or Chi-sq. / Fisher’s exact test (the difference in cumulative incidence between screening trials for that row).  
§ Percentages are row percentages, i.e. the percentages of participants for that row who developed lung cancer during follow-up. 
║¶ Percentages presented for females (║) or males (¶) only. 
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Overall characteristics of participants in PLCO and NLST pooled data 
 
A personal history of any cancer was reported by 4.4% of the pooled samples, the 
overwhelming majority of whom (94.5%) had only one previous cancer. The most 
common previous cancer type reported among both trials combined was female breast 
cancer (n=3,441), representing 44.4% of all previous cancers for which the specific site 
was available (n=7,754). A total of 506 (0.2%) people had two or more previous cancers. 
Of those with a personal history of cancer and for whom the age at diagnosis was 
reported, 78.6% reported at least one cancer diagnosis before the age of 60. SPLC 
developed in 4.0% of the 9,205 cancer survivors in the study and 4.0% of ever-smoking 
cancer survivors developed SPLC compared to only 0.4% of never-smokers. 
4.1 Participant characteristics 
Comparing PLCO and NLST participants 
The mean age in each trial was similar: 62.6 for the PLCO group and 61.4 for the NLST 
participants. A higher proportion of the NLST participants were male compared to the 
PLCO trial (59.0% vs. 49.5%). In both cohorts, the majority of the patients were white 
(85.6% and 89.6% for PLCO and NLST participants respectively) and the distribution of 
education levels was similar between both trials. Most (69.6% of PLCO and 68.1% of 
NLST participants) had some form of post high school education. A higher proportion of 
NLST participants had been diagnosed with COPD (17.5% vs. 6.3% among PLCO 
patients). Compared to the PLCO group, the NLST had a higher proportion of current 
smokers (48.2% vs. 10.4%). NLST ever-smokers, on average, smoked more cigarettes 
per day (28.4 vs. 24.7) for a greater number of years (39.8 vs. 27.7) but the mean quit 
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time among former smokers was higher in the PLCO (20.2 vs. 7.3 years). All contrasts 
for these characteristics were statistically significant (p < .001). 
In terms of previous cancer, a similar proportion of participants in each trial had 
been previously diagnosed with at least one type of cancer (4.5% of PLCO participants 
and 4.3% of the NLST cohort) though the difference was statistically significant (p = 
.007). The most common types of previous cancer reported were breast cancer (3.5% and 
3.4% in the females in the PLCO and NLST trials, respectively) and cervical cancer, 
which was statistically significantly higher (p < .001) in the NLST trial (3.5%) compared 
to the PLCO (0.8%). Previous bladder cancers were more than twice as frequent in the 
NLST (0.5% vs 0.2%; p < .001) compared to the PLCO and colorectal cancers were more 
frequent in the NLST than in the PLCO (0.4% vs. <0.1%; p < .001). The latter finding is 
expected since previous colorectal cancer was an exclusion criterion for the PLCO, but 
some people who reported having it were inadvertently included in the trial. In general, 
absolute differences in proportions of previous cancer types were generally very small. 
Lung cancer survivors were supposed to be excluded from both screening trials so the 
small numbers that were included (n=7 and n=20 for the PLCO and NLST, respectively) 
may not be representative of all participants who would otherwise have been eligible. The 
NLST contained a higher proportion of lung cancer survivors but in absolute terms the 
number was still small (n=20). A similar proportion of PLCO and NLST participants 
were previously diagnosed with cancer before the age of 60 (3.3% vs 3.7%, respectively). 
All contrasts for these characteristics were statistically significant (p < .001). 
Impact of participant characteristics on cumulative incidence of lung cancer. 
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In the PLCO, the cumulative lung cancer incidence was higher among males than 
females, 1.3% vs. 0.8%, respectively, but no difference between men and women was 
seen for NLST participants (3.6% for both sexes). In the PLCO, lung cancer incidence 
was highest for Blacks (1.7%) whereas in the NLST, Native Americans showed the 
highest incidence (4.7%). The cumulative lung cancer incidence was statistically different 
between the PLCO and NLST for each race/ethnicity except Pacific Islanders (p = .176). 
In both trials, those who did not have at least a high school education had the highest 
incidence of lung cancer (2.1% and 5.3% in the PLCO and NLST respectively). Those 
with a family history of lung cancer in the PLCO had a 100% increased risk of lung 
cancer relative to those with no family history of the disease. The increase in lung cancer 
risk among NLST participants with a family history of lung cancer was 26%. Participants 
in the PLCO with COPD had a 233% increased risk of lung cancer compared to those 
without COPD. Among NLST participants, the increase was 72% between those with and 
without COPD. Current smokers in the PLCO had 20 times the risk of lung cancer 
compared to never-smokers (cumulative incidence of 9.0% vs. 0.4%).  
Having a personal history of cancer increased the risk of lung cancer by 60% and 
57% in PLCO and NLST participants, respectively. Being previously diagnosed with two 
or more previous cancers increased the risk of lung cancer, compared to being previously 
diagnosed with only one, by 6% for PLCO participants and 11% for those in the NLST. 
In both trials, lung cancer incidence was higher in those previously diagnosed with cancer 
at age 60 or above, compared to those diagnosed before age 60. Compared to those not 
previously diagnosed with the disease, PLCO lung cancer survivors had 26 times the risk 
of SPLC and lung cancer survivors in the NLST had 14 times the risk of SPLC. The 
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second and third largest effects were seen for survivors of nasopharyngeal and laryngeal 
cancers in the PLCO with relative risks for SPLC of 7.5 and 4.0, respectively, compared 
to having no history of that type of cancer. 
4.2 Key study findings 
Are any specific types of previous cancers strong independent predictors of subsequent 
lung cancer?  
Previous cancers at several different tumour sites were associated with lung cancer 
diagnosis during follow-up. Results from several separate logistic regression models, one 
for each previous cancer type, are presented in Table 4.3.  
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Abbreviations: BMI: Body mass index; CI: Confidence interval; COPD: Chronic obstructive pulmonary disease; N: Number; N/A – Association could be not calculated as data for this cancer were not present; NLST: 
National Lung Screening Trial; PLCO: Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. 
* Adjusted for age, race/ethnicity, education level, BMI, COPD diagnosis, family history of lung cancer, smoking status, intensity and duration and quit time. Robust standard errors were used to account for 
correlations resulting from cluster sampling by study centres. 
† ‡ Estimates calculated among males only (‡ prostate, testicular; n=108,214) or females only († breast, cervical, uterine, n= 100,138). 
§ A single participant who developed lung cancer but did not report having this kind of previous cancer was treated as if they did have it to avoid complete separation of odds ratio estimation. 
║ Risk estimates could not be obtained for survivors of pancreatic cancer because of problems with collinearity. 
Table 4.3 – Odds ratios for future lung cancer by previous cancer type (relative to no previous cancer of that type) for  
PLCO (N=154,900) and NLST (n=53,452) participants 
 PLCO NLST 
  Unadjusted Adjusted *  Unadjusted Adjusted * 
Previous cancer type N Odds Ratio (95% CI); P-value N Odds Ratio (95% CI); P-value 
Breast† 2,702 4.03 (0.54 – 30.1); .175 1.22 (0.70 – 2.13); .480 739 1.54 (1.11 – 2.15); .010 1.25 (0.88 – 1.76); .213 
Digestive       
Colorectal 24 3.92 (0.53 – 29.0); .181§ 2.94 (0.23 – 37.0); .404§ 230 1.09 (0.55 – .2.13); <.001 0.77 (0.27 – 2.15); .623 
Esophageal 28 3.36 (0.46 – 24.7); .234§ 1.82 (0.21 – 15.8); .588§ 20 1.41 (0.19 – 10.5); .739 1.09 (0.17 – 7.10); .931 
Pancreatic 18 -║ -║ 7 -║ -║ 
Stomach 55 1.71 (0.24 – 12.4); .596§ 1.06 (0.14 – 8.02)§ 27 1.03 (0.14 – 7.59); .977 0.71 (0.10 – 5.19); .734 
Endocrine       
Thyroid 342 0.28 (0.04 – 1.97); .200 0.46 (0.08 – 2.85); .406 83 1.00 (0.32 – 3.18); .995 1.11 (0.39 – 3.23); .842 
Genitourinary       
Bladder  323 1.79 (0.80 – 4.01); .160 0.96 (0.57 – 1.61); .875 272 2.06 (1.29 – 3.29); .002 1.43  (0.86 – 2.40); .169 
Kidney 214 1.35 (0.43 – 4.22); .607 0.93 (0.35 – 2.49); .884 68 1.67 (0.61 – 4.60); .318 1.22 (0.50 – 2.98); .663 
Prostate‡ 35 2.32 (0.32 – 16.96); .408 2.88 (0.21 – 39.1); .426§ N/A N/A N/A 
Testicular‡§ 78 0.98 (0.14 – 7.05); .984§ 1.04 (0.16 – 6.72); .969§ N/A N/A N/A 
Gynecologic†       
Cervical 600 2.08 (1.11 – 3.90); .023 1.26 (0.82 – 1.95);.291 765 1.11 (0.77 – 1.62); .567 0.96 (0.68 – 1.37); .840 
Uterine 532 2.58 (1.41 – 4.71); .002 2.01 (1.09 – 3.71); .026 N/A N/A N/A 
Head and neck       
Laryngeal 92 4.28 (1.57 – 11.67); .005 1.36 (0.58 – 3.18); .481 46 1.22 (0.29 – 5.02); .786 0.73 (0.20 – 2.68); .634 
Nasopharyngeal 12 8.54 (1.10 – 66.22); .040 7.62 (0.35 – 166.20); .197 29 1.98 (0.47 – 8.35); .350 1.11 (0.89 – 2.39); .169 
Oral  N/A  N/A  N/A 103 3.88 (2.17 – 6.96); <.001 3.02 (1.41 – 6.45); .004 
Hematologic       
Hodgkin lymphoma 73 1.32 (0.18 – 9.53); .781 1.39 (0.17 – 11.64); .762 N/A N/A N/A 
Non-Hodgkin lymphoma 215 1.78 (0.66 – 4.80); .253 1.05 (0.14 – 8.11) .962 N/A N/A N/A 
Lung 7 37.63 (7.30 – 194.09); <.001 17.39 (3.14 – 96.13); <.001 20 26.89 (11.18 – 64.69); <.001 35.12 (10.8 – 114.6); <.001 
Any 6,897 1.60 (1.32 – 1.95); <.001 1.39 (1.13 – 1.72); .002 2,308 1.58 (1.32 – 1.91); <.001 1.32 (1.08 – 1.61); .006 
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Previous cancer types among PLCO participants 
Breast cancer was the most common type of previous cancer reported among PLCO 
participants (n=2,702), followed by cervical cancer (n=600). Other frequent previous 
cancer types were uterine (n=532), thyroid (n=342) and bladder cancers (n=323). The 
largest clinically relevant effect was observed, after adjustment, for a history of previous 
nasopharyngeal (OR = 7.62; 95% CI: 0.35 – 166.20). Prostate cancer survivors had an 
almost three-fold increased risk of SPLC but the small sample size (n=35) meant the 
confidence interval for the estimate was imprecise (OR = 2.88; 95% CI: 0.21 – 39.1). 
Despite being an exclusion criterion for the PLCO trial, previous lung cancer was 
reported among some participants and was strongly associated with subsequent primary 
lung cancer (SPLC) (OR = 17.39; 95% CI: 3.14 – 96.13) though an estimate from such a 
small number of observations (n=7) should be interpreted with caution. In descending 
order of magnitude, other notable effects were seen for survivors of colorectal (OR = 
2.94; 95% CI: 0.23 – 37.0), uterine (OR = 2.01; 95% CI: 1.09 – 3.71) and esophageal 
carcinomas (OR = 1.82; 95% CI: 0.21 – 15.8), Hodgkin lymphoma (OR = 1.39; 95% CI: 
0.17 – 11.64) and laryngeal cancer (OR = 1.36; 95% CI: 0.58 – 3.18). Women with 
cervical (OR = 1.26; 95% CI: 0.82 – 1.95) or breast cancer (OR = 1.22; 95% CI: 0.70 – 
2.13) had elevated odds of developing lung cancer, however neither association was 
statistically significant.  
Previous cancer types among NLST participants 
Cervical cancer was also the most common type of previous cancer reported among 
NLST participants (n=765), closely followed by breast cancer (n=739). Other notable 
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previous cancer types were bladder (n=272) and colorectal (n=230). The strong 
association between previous lung cancer and SPLC among PLCO participants was 
replicated in the NLST cohort (OR 35.12; 95% CI: 10.8 – 114.6). The second strongest 
association for NLST participants was observed for those who reported having previous 
oral cancer, for whom the odds of SPLC was three times as high relative to those who 
had never had oral cancer oral (OR = 3.02; 95% CI: 1.41 – 6.45). In descending order of 
magnitude, an increased SPLC risk was also seen following previous bladder cancer (OR 
1.43; 95% CI: 0.86 – 2.40), breast cancer (OR = 1.25; 95% CI: 0.88 – 1.76), kidney (OR 
1.22; 95% CI: 0.50 – 2.98) and esophageal cancer (OR = 1.09; 95% CI: 0.17 – 7.10). 
Information on previous oral cancer was only available for participants of the NLST so 
this association could not be tested among PLCO participants.  
Is the number of previous cancers with which a person has been diagnosed an important 
predictor of future lung cancer? 
The results for logistic regression models to assess the association between the number of 
previous cancers and subsequent lung cancer risk are shown in Table 4.4.  
Table 4.4 - Odds ratios for SPLC by number of previous cancers (relative to none) for 
PLCO (N=154,900) and NLST (N=53,452) participants 
 
 PLCO NLST 
                   Unadjusted                              Adjusted*                   Unadjusted                              Adjusted* 
Number of 
previous 
cancers 
 
 
N 
 
 
Odds Ratio (95% CI); P-value 
 
 
  N 
 
 
Odds Ratio (95% CI); P-value 
1 6,491 1.60 (1.31 – 1.95); <.001 1.40 (1.14 – 1.71); .001 2,208 1.58 (1.30 – 1.91); <.001 1.32 (1.09 – 1.60); .005 
2+ 406 1.70 (0.80 – 3.60); .164 1.35 (0.57 – 3.22); .498 100 1.75 (0.77 – 4.00); .184 1.10 (0.42 – 2.88); .849 
 
Abbreviations: BMI: Body mass index; CI: Confidence interval; COPD: Chronic obstructive pulmonary disease; N: Number; NLST: National Lung 
Screening Trial; PLCO: Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial; SPLC: Subsequent primary lung cancer. 
* Adjusted for age, race/ethnicity, education level, BMI, COPD diagnosis, family history of lung cancer, smoking status, intensity and duration and quit 
time. Robust standard errors were used to account for correlations resulting from cluster sampling by study centres. 
 
The unadjusted effect of having a previous cancer on SPLC risk was higher, in 
both trials, for those with more than one previous cancer than with just one. However, the 
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effect estimates for the latter group were imprecise (wide confidence intervals) and the 
increase in effect size compared to having only had one previous cancer did not persist 
after adjustment. Among PLCO participants, in adjusted analysis relative to those with no 
previous cancer the odds ratio for SPLC for those diagnosed with two or more previous 
cancers was 1.35 (95% CI: 0.57 – 3.22) and for those diagnosed with only one previous 
cancer was 1.40 (95% CI: 1.14 – 1.71). A post-estimation test of equality between the 
two categories showed this difference to be statistically insignificant (χ² = 0.01, p = 
0.934). The odds of developing lung cancer relative to those with no previous cancer was 
lower for NLST participants with two or more previous cancers (OR = 1.10; 95% CI: 
0.42 – 2.88) than for those with only one (OR = 1.32; 95% CI: 1.09 – 1.60) but again the 
difference was nonsignificant (χ² = 0.16, p = 0.692). In summary, the effect of a personal 
history of cancer as a risk factor for future lung cancer was not more pronounced in those 
with more than one previous cancer compared with having only one. 
Is being diagnosed with cancer before age 60 years associated with future lung cancer 
risk more strongly than being diagnosed at 60 years or older? 
Risk of lung cancer in those with a personal cancer history compared to those without, 
stratified by age at diagnosis category, are presented in Table 4.5.  
Table 4.5 - Odds ratios for lung cancer (relative to having never had cancer) by age of previous 
cancer diagnosis for PLCO (n=154,900) and NLST (n=53,452) participants 
 
  PLCO  NLST 
  Unadjusted  Adjusted*    Unadjusted Adjusted* 
Age of previous 
cancer onset 
 
N 
 
Odds Ratio (95% CI); P-value 
 
N 
 
Odds Ratio (95% CI); P-value 
60+ 1,606 1.91 (1.34 – 2.74); <.001 1.20 (1.00 – 1.46); .054 319 3.49 (2.46 – 4.95); <.001 1.80 (1.09 – 2.98); .021 
<60 5,123 1.48 (1.18 – 1.87); .001 1.45 (1.07 – 1.96); .016 1,965 1.26 (1.00 – 1.57); .043 1.15 (0.97 – 1.37); .107 
 
Abbreviations: BMI: Body mass index; CI: Confidence interval; COPD: Chronic obstructive pulmonary disease; N: Number; NLST: National Lung 
Screening Trial. PLCO: Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial; SPLC: Subsequent primary lung cancer. 
* Adjusted for age, race/ethnicity, education level, BMI, COPD diagnosis, family history of lung cancer, smoking status, intensity and duration, quit time. 
Robust standard errors were used to account for correlations resulting from cluster sampling by study centres.  
 
  
67 
 
For PLCO participants, the odds ratio for SPLC compared to those with no 
previous cancer was higher among those diagnosed before age 60, compared to those 
diagnosed at 60 or above (OR = 1.45; 95% CI: 1.07 – 1.96 vs. 1.20; 95% CI: 1.00 – 1.46) 
after adjustment for known risk factors, but the difference was not statistically significant 
(χ² = 1.18, p = 0.277). Among NLST participants, the OR for SPLC, relative to those with 
no previous cancer, was lower in those diagnosed before age 60 (1.15; 95% CI: 0.97 – 
1.37) compared to those diagnosed at 60 or older (1.80; 95% CI: 1.09 – 2.98); the 
difference was not statistically significant (χ² = 3.43, p = 0.064). In summary, the 
association between a personal history of cancer and increased future lung cancer risk did 
not appear to be stronger in those diagnosed before age 60, compared to those diagnosed 
at 60 or above. 
Do any of these associations lead to improved lung cancer risk prediction models?  
149,247 participants from the PLCO trial and 53,202 from the NLST were eligible for 
inclusion into risk prediction modeling, when taking the personal history of cancer 
criterion into consideration. Multivariable fractional polynomial analysis of the 
PLCOall2014 model applied to all PLCO participants indicated that smoking intensity 
and the length of time since former smokers had quit smoking both had non-linear 
relationships with 6-year lung cancer risk (Figures 4.1 and 4.2). Suggested 
transformations for both variables were included in all further models as 
‘PLCOall2014mfp’. An interaction term between quit time and former smoker status 
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(0/1) was used to incorporate quit time into the model such that the contribution of quit 
time would only be taken into account for former smokers.  
A test of the PLCOall2014 model applied to all PLCO participants was 
statistically significant, indicating that the set of predictors reliably discriminated 
between those who developed lung cancer and those who did not (-2LL = -6530,0294, χ² 
(16) = 2705.37, p <0.0001). The model demonstrated excellent discrimination among 
PLCO participants (AUC = 0.8552, bias-corrected 95% CI: 0.8450 – 0.8643). The three 
refined measures of a personal history of cancer described in Section 3.3 were substituted 
for the original variable and discrimination was re-tested separately for each candidate. A 
consistent sample size was maintained for each model by ascertaining which one 
included the fewest observations (N=139,053) and re-running all models using only these 
participants. The discrimination performance for these models is summarized in Table 
4.6. 
 
Figure 4.1 Non-linear relationship between smoking 
intensity and lung cancer risk among PLCO smokers  
Probabilities were based on an age of 62 years, white 
race/ethnicity, some college education, a body-mass index 
of 27 kg/m2, no history of COPD/emphysema/chronic 
bronchitis, neither personal nor family history of cancer, 
former smoker status, 27 year smoking history and 10 
years quit time. 
 
Figure 4.2 Non-linear relationship between smoking quit 
time and lung cancer risk among former smokers in the 
PLCO  
Probabilities were based on an age of 62 years, white 
race/ethnicity, some college education, a body-mass index 
of 27 kg/m2, no history of COPD/emphysema/chronic 
bronchitis, neither personal nor family history of lung cancer, 
former smoker status, 27 year smoking history and an 
average smoking intensity of 20 cigarettes/day. 
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Table 4.6 Discrimination performance for logistic 6-year lung cancer models applied to PLCO 
participants (N=139,053 for all models). 
Model +/- covariates AUC (95% CI)* 
PLCOall2014mfp†    0.8552 (0.8450 – 0.8643) 
PLCOall2014mfp - personal history of cancer (0/1) 0.8545 (0.8443 – 0.8636) 
+ personal history of strongly-associated cancers ‡ (0/1)    0.8548 (0.8447 – 0.8640) 
+ personal history of head and neck cancer § (0/1)  0.8546 (0.8441 – 0.8637) 
+ personal history of smoking-related cancer ║ (0/1) 0.8546 (0.8444 – 0.8637) 
PLCOall2014mfp†  
+ number of previous cancers (none, 1, 2+) 0.8552 (0.8450 – 0.8642) 
+ age at previous cancer diagnosis (N/A, 60+,<60) 0.8551 (0.8448 – 0.8641) 
Abbreviations: AUC: Area under the curve; CI: Confidence interval; PLCO: Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. 
* Bootstrap bias-corrected. 
† Includes non-linear transformations for smoking intensity and smoking status-quit time interaction term.  
‡ Breast, prostate, uterine, non-Hodgkin lymphoma or lung. 
§ Nasopharyngeal, laryngeal or oral cancer. 
║ Lung, nasopharyngeal, oral, laryngeal, pancreatic, esophageal, kidney, stomach, bladder, cervical or colorectal. 
 
After removing the variable representing a personal history of cancer at baseline, 
the AUC dropped to 0.8545 (95% CI: 0.8443 – 0.8636). Adding the variable comprising 
cancer types that showed a strong association with SPLC in adjusted analyses (breast, 
prostate, non-Hodgkin lymphoma and lung) only raised the AUC by .0003 (0.8548; 95% 
CI: 0.8447 – 0.8640). Even smaller increases in AUC were seen when substituting a 
personal history of head and neck cancers (0.8546; 95% CI: 0.8444 – 0.8637) or a history 
of smoking-related cancer into the model (0.8546; 95% CI: 0.8444 – 0.8637). None of the 
three refined binary measures of personal cancer history improved model discrimination 
beyond what was achieved using the original term.  
The number of previous cancers (none, 1, 2+) reported did not improve 
discrimination (AUC = 0.8552; 95% CI: 0.8450 – 0.8642), nor did the age at previous 
cancer diagnosis category (AUC = 0.8551; 95% CI: 0.8448 – 0.8641). No evidence of 
interaction between a personal history of cancer and age of previous cancer onset 
(60+/<60 years) was observed when included alongside the PLCOall2014 covariates (p = 
0.787). The PLCOall2014mfp model was re-evaluated among NLST participants as a 
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means of external validation. Performance statistics for each case are summarized in 
Table 4.7. 
Table 4.7 - Performance statistics for the PLCOall2014mfp model by screening trial. 
Statistic PLCO (N=139,212) NLST (N=51,033) 
AUC (95% CI)* 0.855 (0.845 – 0.864) 0.710 (0.698 – 0.721) 
Brier score (95% CI)* 0.0097 (0.0092 – 0.0102) 0.0338 (0.0324 – 0.0353) 
Spiegelhalter’s z-statistic (p-value) 0.2437 (0.4037) 0.1984 (0.4214) 
Median absolute error  0.0026 0.0275 
90th percentile absolute error 0.0289 0.0808 
Abbreviations: AUC: Area under the curve. CI: Confidence interval; N: Number; NLST: National Lung Screening Trial; PLCO: Prostate, Lung,  
Colorectal and Ovarian Cancer Screening Trial. 
* Bias-corrected using bootstrapping of 1000 samples. 
 
Discrimination was considerably lower when the model was applied to the NLST 
(AUC = 0.710). The performance as a whole, as measured by the Brier score, showed a 
similar pattern. The score for the NLST was higher (0.0338; 95% CI: 0.0324 – 0.0353), 
indicating worse performance compared to the PLCO (0.0097; 95% CI: 0.0092 – 0.0102). 
In terms of calibration, the PLCOall2014mfp model achieved a non-significant result for 
the Spigelhalter z-statistic in all cases, indicating a good model calibration in the PLCO 
and NLST. Median and 90th percentile absolute error between observed and predicted 
probabilities were also less favourable when assessed in NLST participants-only, though 
the values were still acceptably low (0.0275 and 0.0808, respectively) and were no cause 
for concern. Bootstrap bias-corrected confidence intervals for both the AUC and Brier 
score from the final model were relatively narrow, suggesting that the model was 
internally valid. In terms of external validity though, the excellent performance of the 
model was not matched when applied to the NLST. The reason for this is that the NLST 
consists only of high-risk ever-smokers, increasing the homogeneity in risk across all 
individuals compared to a general population-based sample containing both ever- and 
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never-smokers. Increased homogeneity makes it more difficult to discriminate between 
those who will get lung cancer (higher risk) and those who will not (lower risk).  
The odds ratios and coefficients for the variables included in the final logistic 
regression model for 6-year lung cancer risk among PLCO participants is summarized in 
Table 4.8. 139,212 observations were used in the final model of a possible 154,900 
PLCO participants, thus 10.1% of the sample did not have sufficient data for this set of 
predictors. While Bennet maintains that estimates are likely to be biased when more than 
10% of data are missing (Bennett, 2001), 10.1% is on the edge of that threshold and a 
simulation study investigating the impact of missing data on secondary analyses of large 
surveys found that results with 10% missing were not biased to any major degree. Only at 
values of 20% or higher did missing data impact their results (Langkamp, Lehman, & 
Lemeshow, 2010). Therefore, imputation of missing data was not undertaken. Finally, 
there were 1,572 occurrences of lung cancer in the PLCO during six years of follow-up. 
This equates to 92 per each of the 17 predictors present in the model, which is higher than 
the recommended minimum of 50 per predictor to minimize overfitting. 
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Table 4.8 - Logistic regression model for 6-year lung cancer risk among PLCO cancer 
screening trial participants (N=136,212) 
Variable Odds Ratio (95% CI) P-value Beta Coefficient 
Age, per 1-yr increase† 1.071 (1.057 – 1.085) <0.001 0.068348 
Race or ethnicity‡    
White 1.000  Reference group 
Black 1.587 (1.294 – 1.946) 0.001 0.461738 
Hispanic 0.679 (0.405 – 1.138) 0.142 -0.38783 
Asian 0.651 (0.435 – 0.973) 0.036 -0.42949 
Native American 1.242 (0.504 – 3.065) 0.638 0.216873 
Pacific Islanders 1.117 (0.548 – 2.28) 0.761 0.110893 
Education, per 1 level increase†§ 0.929 (0.897 – 0.962) <0.001 -0.07321 
Body-mass index, per 1 kg/m2 increase† 0.968 (0.956 – 0.980) <0.001 -0.0328 
Chronic obstructive pulmonary disease (yes vs. no)║ 1.406 (1.220 – 1.619) <0.001 0.340466 
Personal history of cancer (yes vs. no) 1.393 (1.128 – 1.719) 0.002 0.331297 
Family history of lung cancer (yes vs. no) 1.716 (1.498 – 1.965) <0.001 0.53973 
Former smoker (yes vs. no) 17.154 (8.687 – 33.871} <0.001 2.842204 
Current smoker (yes vs. no) 16.666 (9.176 – 30.272} <0.001 2.813396 
Smoking intensity (cigarettes/day) ¶  <0.001 -0.7168 
Smoking duration, per 1-yr increase† 1.044 (1.034 – 1.054) <0.001 0.043233 
Smoking quit time, per 1-yr increase†¶  <.0001 -0.23175 
Model constant   -7.51463 
Abbreviations: CI: Confidence interval; COPD: Chronic obstructive pulmonary disease; PLCO: Prostate, Lung, Colorectal and Ovarian Cancer Screening 
Trial. 
* To calculate the 6-year probability of lung cancer for an individual, do the following: for categorical variables, multiply the beta coefficient  for the 
variable by 1 if the person falls into that category and 0 if not. For variables other than smoking intensity and quit time, subtract the centering value from 
the individual’s value for that factor and multiply the result by the beta coefficient of the variable. For smoking intensity , divide the person’s value by 
100, exponentiate it to the power −0.5, and subtract 2.010432048, then multiplying this number by the beta coefficient of the  variable. For quit time 
duration, add 1 to the person’s value and divide the total by 10, then take the natural log of this number and add .0407789134 to center the value. 
Multiplying the result by the smoking quit time beta coefficient. Sum together each of these components for each predictor as well as the model constant 
to obtain the logit. Finally, convert the logit to a probability using the formula: elogit/(1+ elogit).  
† Age was centered on 62 years, education was centered on level 4, body-mass index was centered on 27 kg/m2, smoking duration was centered on 27 
years. 
‡ As self-reported. 
§ Education level consisted of ordinal groups: less than high-school graduate (1), high-school graduate (2), some training after high school (3), some 
college (4), college graduate (5), and postgraduate or professional degree (6).  
║ COPD variable also encompasses diagnoses of emphysema and chronic bronchitis.  
¶ Smoking intensity (average number of cigarettes smoked per day) and smoking quit time (duration in years) had nonlinear associations with lung 
cancer, and these variables were transformed. For this reason, meaningful interpretations of their odds ratios directly are not possible. 
 
Overall, considerable increases in SPLC risk were observed for those with 
previous lung cancer and female breast cancer survivors in both trials. Marked elevations 
in risk were observed for prostate and uterine cancer as well as non-Hodgkin lymphoma 
survivors but these effects were only estimable for PLCO. Similarly, the increased SPLC 
observed in NLST participants with previous oral cancer could not be re-evaluated in 
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PLCO participants. Only the associations with previous lung cancer (both trials), oral 
cancer (NLST only) and uterine cancer (PLCO) were statistically significant. 
The number of previous cancers was not an important factor in future lung cancer 
risk, nor was being diagnosed with any cancer before age 60 compared with at 60 or 
above. More refined variables representing personal cancer history did not improve lung 
cancer risk prediction by a considerable amount when compared to the simple binary 
‘personal history of cancer (yes/no)’ predictor present in the most current lung cancer risk 
prediction model. A detailed discussion of these findings in context will be presented in 
the following chapter. 
4.3 Assumptions Testing 
In order to test for misspecification error for the final model, a specification link test was 
performed following model estimation. The _hatsq term was statistically significant (p = 
0.001) which suggests that important predictors or interaction effects might be missing 
from the model or the logit function is incorrectly specified. However, the significant 
result might be due to the large sample size used and excellent discrimination and 
calibration performance suggest that assumption of correct model fit holds for the model. 
Non-linear relationships were accounted for with transformations and all a priori 
interactions tested were found to be non-significant.  
Pearson, deviance and Pregibon leverage residuals were plotted for all 
participants in the sample after fitting the final model (Figures. 4.3 – 4.5). Only a 
relatively small number of observations showed any deviation from the rest of the sample 
and the leverage statistics showed that these observations contributed negligible amounts 
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to the overall model performance individually, so removal of these participants was 
deemed unnecessary. 
 
 
 
 
 
 
 
 
 
Collinearity diagnostics were run for all variables included in the final model. No 
problematic degree of multicollinearity was observed since no variance inflation factor 
(VIF) exceeded 10, the accepted threshold for high multicollinearity (Kutner, 
Nachtsheim, & Neter, 2004). The highest VIF observed was for smoking duration (4.89), 
followed by smoking status (4.86) and the mean VIF was 1.64. 
Figure 4.3. Pearson residuals for PLCOall2014mfp 
model applied to PLCO participants (n=139,212). 
 
Figure 4-4. Deviance residuals for the 
PLCOall2014mfp model applied to PLCO participants 
(n=139, 212). 
 
Figure 4.5. Leverage of each observation in the sample 
after applying PLCOall2014mfp to PLCO participants 
(n=139, 212). 
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CHAPTER 5 - DISCUSSION AND CONCLUSIONS 
5.1 Discussion 
5.1.1 Sample characteristics 
The approximate 60% increase in SPLC risk in cancer survivors relative to those with no 
personal history of cancer, was consistent between the two trials. Directly comparable 
estimates elsewhere are not readily available but this increase is much larger than the 6% 
higher SPLC risk reported for Japanese cancer survivors (SIR: 1.06; 95% CI: 1.01 – 1.11) 
(Utada et al., 2014). The difference could be attributable to several factors including 
differences in participants’ characteristics and follow-up periods. Although no follow-up 
statistics were presented for the development of SPLC specifically, the median and mean 
follow-up durations for all cancers combined were both lower in the study by Utada and 
colleagues (1.8 years and 4.3 years, respectively) (Utada et al., 2014) than the 6-year 
follow-up duration for the current analysis. 
5.1.2 Previous cancer sites associated with subsequent primary lung cancer risk 
Those who reported having a previous history of any cancer have a 39% increased odds 
of SPLC after adjustment for known risk factors. The closest comparable estimate from 
population cancer registries was published by Utada and colleagues (2014); the 
researchers reported a 6% increased odds of lung cancer following previous cancer at any 
site (SIR = 1.06; 95% CI: 1.01 – 1.11) among Japanese cancer survivors (Utada et al., 
2014) but the median follow-up of 8 months was substantially shorter than the current 
study.  
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The effects (or lack thereof) observed in the current study are discussed separately 
below. The majority of the previous cancer types investigated failed to show positive, 
significant associations with lung cancer which may indicate that many of the 
associations reported in previous studies are subject to confounding but could also be due 
to lack of statistical power compared to other studies that used larger SEER and 
population-wide cancer registry datasets. 
Lung 
The site of previous cancer most strongly associated with SPLC was the lung with odds 
ratios of 17.4 (95% CI: 3.14 – 96.13) and 35.1 (95% CI: 10.8 – 114.6) in the PLCO and 
NLST, respectively, but both estimates should be interpreted with caution since they are 
derived from very small numbers of lung cancer survivors (n=7 and n=20, respectively). 
The risk of developing SPLC following resection of non-small cell lung cancer (NSCLC) 
has been estimated at approximately 1-2% per person per year (Johnson, 1998). Lou and 
colleagues reviewed the outcomes of 1,294 patients with early-stage NSCLC who 
underwent surgical resection and found that 7% developed SPLC; SPLC risk varied from 
3-6% per person-year (Lou et al., 2013). The effects of chest irradiation and continued 
cigarette smoking after an initial lung cancer have both been shown to contribute to 
SPLC risk (Heyne, Lippman, Lee, Lee, & Hong, 1992; Johnson, 1998; Richardson et al., 
1993; Tucker et al., 1997). 
Breast  
Although previous studies have investigated the risk of subsequent primary cancer (SPC) 
among breast cancer survivors (Andersson et al., 2008; Mellemkjær et al., 2006), few 
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have investigated SPLC specifically and many of those compared the effects of 
treatments (Andersson et al., 2008; Catsburg, Kirsh, Soskolne, Kreiger, & Rohan, 2014; 
Grantzau, Mellemkjær, & Overgaard, 2013; Lorigan, Califano, Faivre-Finn, Howell, & 
Thatcher, 2010), smoking (Catsburg et al., 2014; Ford et al., 2003; Kaufman et al., 2008; 
Neugut et al., 1994) and estrogen receptor (ER) status among survivors rather than 
comparing those with previous breast cancer to those without (Schonfeld, Curtis, 
Anderson, & de Gonzalez, 2012). This makes comparisons between the current study and 
previous research less than straightforward. Studies that reported increased risks for 
SPLC, typically only did so among sub-groups, particularly those whose breast cancer 
was diagnosed before menopause (Evans et al., 2001; Harvey & Brinton, 1985). Evans 
and colleagues reported an increased SPLC risk among women diagnosed before age 50 
but found a protective effect for women diagnosed at age 50 or older (Evans et al., 2001). 
Raymond and Hogue (2006) reported increased SPLC risk among breast cancer survivors 
but standardized incidence ratios (SIRs) were presented separately by age bracket so an 
overall estimate is not available for comparison, despite statistically significant positive 
associations which increased with each age bracket (Raymond & Hogue, 2006).  
In the current analysis, the adjusted associations were not statistically significant 
in either PLCO (OR = 1.22; 95% CI: 0.70 – 2.13) or NLST participants (OR = 1.25; 95% 
CI: 0.88 – 1.76). This result is similar to the findings of recent studies which reported 
increased SPLC risk among breast cancer survivors when age at breast cancer diagnosis 
was not considered (Andersson et al., 2008; Hemminki et al., 2005; Utada et al., 2014). 
Explanations for the elevation in SPLC among breast cancer survivors include the effects 
of radiation exposure during cancer treatment and continued cigarette smoking, as well as 
  
78 
 
ER status as those with ER- tumours are at higher risk of SPLC compared to those with 
ER+ breast cancers (SIR = 1.22; 95% CI: 1.10 – 1.37) (Kaufman et al., 2008; Neugut et 
al., 1994; Schonfeld et al., 2012). 
Digestive  
In the NLST, a protective effect on SPLC risk was observed among colorectal cancer 
survivors but the effect was statistically nonsignificant with a wide confidence interval, 
thus not allowing for any meaningful conclusions to be drawn (OR = 0.77; 95% CI: 0.27 
– 2.15). Should a true association exist between colorectal cancer and SPLC, it may be 
attributable to several possible mechanisms including misclassification of metastases as 
new primary cancers as well as shared genetic risk factors (Emi et al., 1992; Korošec, 
Glavač, Rott, & Ravnik-Glavač, 2006).  Colorectal and lung cancers both share smoking 
as a risk factor (Botteri et al., 2008; Liang, Chen, & Giovannucci, 2009) and the epithelia 
of both tissues may respond similarly to environmental carcinogens and epigenetic 
changes since they both of endodermal origin. 
In PLCO participants, the increase in SPLC risk seen among esophageal cancer 
survivors (OR = 1.82; 95% CI: 0.21 – 15.8) fell within the range of statistically 
significant hazardous associations reported in other studies (Chuang, Hashibe, et al., 
2008; Jégu et al., 2014; Zhu et al., 2012) but the effect was statistically nonsignificant 
and markedly lower than the three- and four-fold increases in risk reported by Zhu et al. 
(2012) (OR = 3.19; 95% CI: 2.12 – 4.61) and Jégu et al. (2014) (OR = 4.25, CI not 
presented), respectively. Large increases in SPLC risk have been reported in several 
previous studies among esophageal cancer survivors in the general population (Chuang, 
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Hashibe, et al., 2008; Jégu et al., 2014; Utada et al., 2014; Zhu et al., 2012) but these 
studies were not well adjusted for lung cancer risk factors, especially smoking-related 
ones. The unadjusted effect in the PLCO was similar (OR = 3.36; 95% CI: 0.46 – 24.7) 
but the effect was non-significant and was not replicated in the NLST. After adjustment, 
only a small increase in lung cancer risk was observed among esophageal cancer 
survivors and the effect was not statistically significant (OR = 1.09; 95% CI: 0.17 – 7.10) 
however, the confidence interval is wide and includes effects found to be significant in 
previous studies. Associations between esophageal cancer and lung cancer may be 
attributable to a “field cancerization” effect whereby the carcinogenic effects of alcohol 
and tobacco may act on different parts of the aerodigestive tract simultaneously  causing 
multiple independent cancers to occur at various sites (Slaughter, Southwick, & Smejkal, 
1953). 
The adjusted effects observed for stomach cancer survivors in both the PLCO 
(OR = 1.06; 95% CI: 0.14 – 8.02) the NLST (OR = 0.71; 95% CI: 0.10 – 5.19) were both 
statistically nonsignificant with wide confidence intervals, so no accurate sense of the 
true effects could be drawn from these estimates. 
Endocrine 
Estimates for the effect of previous thyroid cancer on SPLC risk vary in other studies 
from statistically nonsignificant null effects (Canchola et al., 2006; Rubino et al., 2003) 
to statistically significant hazard (C.-H. Lu et al., 2013; Utada et al., 2014) or protective 
effects (A. P. Brown et al., 2008; Verkooijen et al., 2006). Thyroid cancer survivors of 
the PLCO were not at increased risk for SPLC after adjustment (OR = 0.46; 95% CI: 0.08 
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– 2.85). A small increase in risk was seen among NLST thyroid cancer survivors but this 
was not statistically significant (OR = 1.11; 95% CI: 0.39 – 3.23). The effects in both the 
PLCO and NLST had wide confidence intervals, thus the estimates are imprecise, but the 
upper limit tells us that the association between thyroid cancer and SPLC is unlikely to be 
of a very large magnitude. 
Genitourinary 
An increased lung cancer risk was observed for kidney cancer survivors in previous 
studies by Czene & Hemminki (2002) (SIR = 1.36) and Utada and colleagues (2014) 
(SIR = 1.29); both types of cancer share smoking as a risk factor. An increase in lung 
cancer risk of similar magnitude to those reported previously was seen among kidney 
cancer survivors in the NLST after adjustment but was not statistically significant (OR = 
1.22; 95% CI: 0.50 – 2.98) and no significant elevation in SPLC risk was seen in PLCO 
participants previously diagnosed with kidney cancer (OR = 0.93; 95% CI: 0.35 – 2.49).  
A clinically relevant increase in SPLC risk was seen following prior bladder 
cancer in NLST participants (OR = 1.43; 95% CI:: 0.86 – 2.40) but the effects was not 
statistically significant and not replicated in PLCO participants (OR = 0.96; 95% CI:: 
0.57 – 1.61). The almost three-fold increased risk of SPLC (OR = 2.88; 95% CI: 0.21 – 
39.1) seen in prostate cancer survivors is unusually high but the confidence interval for 
the estimate is so wide that the estimate may not be reflective of any true effect.  
Gynecologic 
Tobacco smoking could partly explain increases in SPLC among cervical cancer 
survivors since it is an established cofactor in HPV-mediated cervical carcinogenesis 
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(Fonseca-Moutinho, 2011). The increases in SPLC risk among survivors of cervical 
cancer reported in previous studies (Hemminki et al., 2000; Jégu et al., 2014) were 
replicated before controlling for confounding in both the PLCO and NLST cohorts. A 
marked increase in risk persisted for cervical cancer survivors in the PLCO after 
adjustment (OR = 1.26; 95% CI: 0.82 – 1.95) but the effect was nonsignificant and not 
reproduced among NLST participants (OR = 0.96; 95% CI: 0.68 – 1.37).  
Among PLCO participants, those with prior uterine cancer (n=532) were twice as 
likely to develop subsequent lung cancer compared to those without (OR = 2.01; 95% CI: 
1.09 – 3.71). The magnitude of this effect was roughly 40-70% higher than has been 
reported in previous studies among the general population relative to the null of 1.00 
(Jégu et al., 2014; Koivisto-Korander et al., 2012). As suggested by Koivisto-Korander et 
al., miscoding of recurrent uterine cancers may explain part of the association since the 
lungs are one of the most common sites of uterine cancer metastases occurring in around 
7-8% of patients (AlHilli & Mariani, 2013) but this is unlikely to account for such a large 
effect. Smoking has a protective effect on uterine cancer through antiestrogenic effects 
such as weight loss and earlier onset of menopause (Michnovicz, Hershcopf, Naganuma, 
Bradlow, & Fishman, 1986) but this appears to be exclusive to postmenopausal women 
(Zhou et al., 2008). A large European cohort showed a twofold increased risk of 
endometrial cancer in premenopausal current smokers compared to never-smokers (Al-
Zoughool et al., 2007). It has been suggested that polycyclic aromatic hydrocarbons in 
tobacco smoke may cause chronic anovulation, an established risk factor for endometrial 
cancer (Haidopoulos et al., 2010; Kaaks, Lukanova, & Kurzer, 2002). Information on 
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previous uterine cancer was not present in the NLST dataset so the association could not 
be re-evaluated.  
Head and Neck 
Previous head and neck cancers have been associated with some of the highest increases 
in SPLC risk based on estimates from previous studies (Chen et al., 2011; Chuang, Scelo, 
et al., 2008; Jégu et al., 2014; Morris, Sikora, Patel, Hayes, & Ganly, 2010; Utada et al., 
2014) and lung cancer is the most common subsequent primary malignancy following 
squamous cell cancer of the head and neck (45.8%) (Griffioen et al., 2015). Although the 
etiology of SPLC following cancer of the head and neck remains unclear, most cancers of 
the head and neck are strongly associated with a history of cigarette smoking 
(Licciardello et al., 1989). It has been suggested that metastatic SCCs of the head and 
neck are particularly prone to being misclassified as SPLC (Geurts et al., 2005; 
Kuriakose et al., 2002; Ritoe et al., 2002). 
When combined into a single group, survivors of previous head and neck cancers 
in the PLCO had a 75% increased odds of SPLC after adjustment but the effect was 
nonsignificant (OR = 1.75; 95% CI: 0.62 – 4.92). This is markedly lower than the effects 
reported by Chuang et al. (SIR = 3.30) and Jégu et al. (SIR = 8.71 for males and 18.81 for 
females) but neither of these studies controlled for smoking-related exposures which are 
potential confounders of an association with SPLC (Chuang, Scelo, et al., 2008; Jégu et 
al., 2014). Previous nasopharyngeal and (OR = 7.62; 95% CI: 0.35 – 166.2) laryngeal 
cancers (OR = 1.36; 95% CI: 0.58 – 3.18) were associated with considerable increases in 
SPLC risk among PLCO participants, but the effect was of much smaller magnitude in 
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NLST cohort (OR = 1.11; 95% CI: 0.89 – 2.39). A greatly elevated risk of SPLC was 
observed for those with previous oral cancer (OR = 3.02; 95% CI: 1.41 – 6.45) and the 
effect was statistically significant but this was only measured in the NLST.  
Hematologic 
Several studies, including a meta-analysis of 21 investigations of survivors of Hodgkin 
lymphoma have reported a 4-fold increased risk of SPLC compared to the general 
population (Ibrahim et al., 2013; Jégu et al., 2014). The effects of smoking and 
radiotherapy are both established risk factors for SPLC in Hodgkin lymphoma survivors 
(Ibrahim et al., 2013). The increase in SPLC risk seen among Hodgkin lymphoma 
survivors in the PLCO was markedly lower than previous studies but still of clinically 
important magnitude (OR = 1.39; 95% CI: 0.17 – 11.64). 
In addition to smoking and radiation exposure, a distinct dose-response 
relationship between the use of alkylating chemotherapy agents and SPLC risk has been 
demonstrated among those treated for non-Hodgkin lymphoma (Travis et al., 2002). 
Survivors of non-Hodgkin lymphoma in the PLCO were not at increased risk for SPLC 
after adjustment (OR = 1.05; 95% CI: 0.14 – 8.11). This result contrasts with several 
other studies that reported SPLC as the most common type of SPC among non-Hodgkin 
lymphoma survivors (Travis et al., 2002).  
5.1.3 Number of previous cancers  
Being previously diagnosed with more than one cancer had a greater impact on SPLC 
risk for NLST participants whose cumulative incidence of SPLC increased by 11% 
(relative to those with only one previous cancer) compared to PLCO participants for 
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whom the increase was only 6%. However, these effects did not persist after adjustment 
for other major risk factors and the differences between the groups were not statistically 
significant. Thus, there was no evidence in the current study that those with more than 
one previous cancer are at a higher risk of lung cancer than those with only one. To the 
best of our knowledge, this is the first study to specifically investigate the influence of the 
frequency of previous cancers of any type with respect to future lung cancer risk. The 
proportion of participants with more than one previous cancer was smaller than in other 
studies so it could be that there were too few instances present to detect any considerable 
elevation in risk. 
5.1.4 Age of previous cancer onset 
Being diagnosed before age 60 does not appear to affect the association between previous 
cancer and future lung cancer. This conclusion is supported by the lack of any effect 
modification between personal cancer history and age of previous cancer onset when 
testing a priori interactions. The lack of any increased lung cancer risk seen in the 
younger age at diagnosis group could in part be due to the fact that the vast majority 
(78.6%) of cancer survivors in the study were diagnosed before age 60. There is a much 
greater duration over which to develop lung cancer up to age 60 than between 60 and 74 
years, the upper limit for enrolment in both trials, so it could be that those diagnosed after 
age 60 were too few in number for any difference between the age groups to manifest 
itself. 
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5.1.5 Predictive utility of these factors 
None of the factors investigated here improved the discrimination of the existing 
PLCOall2014 model to any considerable degree. None of the refined variables 
representing a personal history of specific cancer types demonstrated as much predictive 
utility as the original term included in the current model. When applying the final model 
(PLCOall2014mfp) to all PLCO participants, the point estimate for the AUC (0.855) is 
slightly higher than that reported by Tammemagi (2014) (AUC = 0.848); the latter was 
derived from participants in the PLCO intervention arm only (n = 77,445) so this is likely 
as a result of the increased sample size used to test the model and the point estimate lies 
within the 95% CI for the AUC reported by Tammemagi (2014) (0.833 – 0.861) 
suggesting that the increase is unlikely to be a significant one. The difference could also 
be in part due to slightly different non-linear transformations used as well as the larger 
sample and updated dataset. The final model did not perform as well when applied to 
NLST participants (AUC = 0.710). The narrowness of the bootstrap bias-corrected 95% 
CIs suggest that the performance statistics for the final model are robust, i.e. they are not 
sensitive to small changes in the data and therefore the model should perform similarly in 
populations with characteristics that are comparable to those of the development sample. 
Low median and 90th percentile absolute errors indicate good calibration when applied to 
the PLCO, NLST and both samples combined.  
5.1.4 Limitations 
Perhaps one of the most important limitations of any investigation into the effects of 
previous cancers on SPLC risk is that multiple primary malignancies in the same 
individual is uncommon. Population-wide cancer registries afford researchers the largest 
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numbers of occurrences but are limited in their ability to adjust for influential cofactors. 
Even though the PLCO and NLST are large trials, low numbers of specific previous 
cancer types limit the number of outcome events, leading to wide confidence intervals for 
the effect estimates – often too large to allow meaningful conclusions to be drawn. 
Further limitations are discussed below. 
5.1.4.1 Self-reported occurrences of previous cancer 
A possible source of measurement bias in this study is the accuracy of self-reported 
information on personal cancer history. A few studies investigated this (Bergmann, Calle, 
Mervis, Miracle-McMahill, & Thun, 1998; Desai et al., 2001; Manjer, Merlo, & 
Berglund, 2004; Parikh-Patel, Allen, & Wright, 2003; Schrijvers, Stronks, van de Mheen, 
Coebergh, & Mackenbach, 1994). Each of these studies used mailed questionnaires or in-
person interviews and compared participants’ responses to cancer registry data. Breast 
cancer is the most accurately reported previous cancer type in terms of true positive 
responses (Bergmann et al., 1998; Berthier et al., 1997; Desai et al., 2001). In their study 
of 133,479 current and former Californian teachers, Parikh-Patel and colleagues found 
that the accuracy of self-reported cancer data varied by site. Sensitivity (proportion of 
true positives classified as positive) varied greatly by cancer site, from 94.6% and 92.9% 
for breast and thyroid cancers, to between 80.0 and 85.9% for lung, colorectal and 
ovarian cancers and a markedly poorer 44.3% for cervical cancer (Parikh-Patel et al., 
2003). Specificity (proportion of true negatives classed as negative) ranged from 90.2-
99.9%, but was above 98% for all but one cancer type (‘other skin’). 
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Non-white race has been associated with increased false-positive responses (OR = 
1.34), as has older age (among those 45+ compared to <45) after adjusting for race and 
socioeconomic status (Parikh-Patel et al., 2003). In contrast, other researchers found non-
white race and older age to be predictors of increased false-negative reporting of cancer 
history but the latter finding was only true in those older than the maximum age of the 
participants in the current analysis (74) (Desai et al., 2001). Dominguez and colleagues 
assessed the accuracy of self-reported data in an outpatient breast cancer center. Among 
3,614 women who had a single cancer according to the registry and reported none or one 
cancer on their questionnaire, the overall sensitivity was 85.7%. This varied by cancer 
type from 92.1% for breast cancer to 42.9% for leukemia and white women reported 
breast cancer more accurately (in terms of sensitivity) than did Asian/Pacific Islanders (p 
= 0.008), but no statistically significant differences were found in comparison to black, 
Caribbean or West Indian, or Native American. Older age at the time of the study did not 
have any effect on sensitivity for any group ≥ 45 compared with those aged 44 or 
younger (Dominguez et al., 2007).  
Although the general accuracy of self-reported cancer history data is suspect to 
much variation, this study was not susceptible to the problems associated with reports 
from those aged 75+ as they were not included and since 86.6% of the participants were 
white the influence of inaccuracies observed in non-whites should be minimal (though 
the findings may consequently be less generalizable to them). Although cervical cancers 
were frequently underreported in the study of Californian teachers, the prevalence in the 
current analysis was relatively high in NLST participants, possibly due to the proportion 
of heavy smokers at high risk for the disease. Thus, problems associated with 
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underrepresentation should be of little concern. Reporting the wrong type of previous 
cancer seems more likely than misreporting its occurrence in general, so problems with 
misclassification ought to have a great impact on associations with specific cancer types 
than the crude overall measure. Errors in self-reporting of personal cancer history should 
lead to decreased performance in terms of discrimination and calibration since they are 
dependent upon changes in both sensitivity and specificity. As sensitivity decreases, 
false-negatives increase and as specificity decreases, false-positives increase. Either of 
these scenarios (together or separately) will reduce predictive performance. Although no 
unexpectedly large effects that may have been attributable to differential misclassification 
were seen, it remains possible that some associations apparent in large registry studies 
that have more accurate cancer history classification, may have been underestimated in 
the current study.  
5.1.4.2 Creation of new variables 
For the majority of the cancer types included in the current analyses, dichotomous 
variables representing previous diagnosis had already been created by Information 
Management Systems (IMS). Most of these were measured in both trials such that 
harmonized variables could be created, with the exception of oral cancer which was only 
available for the NLST. Variables for previous prostate, uterine and both non-Hodgkin 
and Hodgkin lymphoma had to be created manually using data from questions only asked 
in the PLCO so associations for these cancers could not be tested among NLST 
participants.  
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The score representing the number of previous cancers was created using as much 
data as possible but differences in the information present for PLCO and NLST 
participants could have led to problems with construct validity (how well the variable 
measures what it intends to measure) to some degree. PLCO participants reported the 
type and age at diagnosis for up to four previous cancers, irrespective of cancer type (i.e. 
subsequent cancers were considered separate even in they were of the same type as the 
first). A score of 0, 1 or 2+ was assigned to PLCO participants according to the number 
of cancers for which the participant had reported the anatomical site (regardless of what 
the sites were) from the variables ‘ph_type1’-‘ph_type4’. However, the information for 
NLST participants was not analogous. Instead, several variables simply indicated the 
presence or absence of specific cancer types. Therefore, a participant with two previous 
cancers of the same type, would be assigned a 1 despite having had two separate previous 
cancers. This means that the number of NLST participants with two or more previous 
cancers may be underestimated since subsequent primary cancers of the same cancer type 
are not considered separate. This underestimation could decrease the statistical power to 
detect differences in risk between those with one previous cancer and those with two or 
more. This could be important since even if 1% of the 2,208 NLST participants denoted 
as having one cancer were misclassified, those 22 people would represent an increase of 
22% to the size of the 2+ group (n=100). 
5.1.4.3 Age at diagnosis cut-off 
Much has been written about the hazards associated with dichotomizing continuous data 
(Baneshi & Talei, 2011; Cumberland et al., 2014; Royston, Altman, & Sauerbrei, 2006). 
Dichotomization of a continuous variable results in a loss of information and in turn, 
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decreases statistical power. It may also lead to an inflation of type I error (Austin & 
Brunner, 2004). Finally there is also the problem of how to choose the most appropriate 
cut-point. 
Age at diagnosis was dichotomized for several reasons, including ease of 
interpretation. If the variable was left in its original continuous form and included in 
prediction models, requiring the participant to know their exact age at diagnosis of their 
initial cancer may result in higher information bias compared to recalling whether their 
initial cancer was diagnosed before a given age. Categorizing the age at diagnosis also 
enables the results to be more easily compared to previous studies. Age 60 was chosen 
based on the sharp increase in 10-year lung cancer risk seen after this age and to 
maximize the number of observations in the < 60 category.  
5.1.4.4 Modeling limitations  
Logistic regression allowed the results of the prediction modeling portion of this study to 
be directly comparable with previous work, however, this modeling technique does not 
capture time-to-event data unlike Cox proportional hazards models (Cox, 1972). Harrell’s 
c statistic (Harrell, Califf, Pryor, Lee, & Rosati, 1982; Harrell, Lee, & Mark, 1996) is the 
equivalent to the AUC. The c statistic for the comparable Cox model for 6-year lung 
cancer risk was only slightly higher, at 0.856 compared to an AUC of 0.855 for the 
logistic.  
The c statistic for a Cox model for 10-year lung cancer risk was computed to 
ascertain whether loss of information by truncating follow-up to 6 years was detrimental 
to predictive performance, but it was found to be lower than the 6-year model (c = 0.850). 
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It is unclear whether the performance deterioration over the longer follow-up period is 
due to a weakening of the association between all of the predictors and the outcome or 
only for some subset of predictors in particular. 
Several of the associations of interest in this study were initially unable to be 
estimated due to problems with complete separation but the solution of intentionally 
misclassifying one participant as a workaround is not without its disadvantages, as have 
been previously alluded to. The likelihood of complete separation diminishes with 
increasing sample size but since these events are rare, minimizing the problem would 
require even greater sample sizes than were available in the PLCO and NLST. Many of 
the associations that were not estimable among PLCO participants were able to be 
calculated among NLST participants. 
5.1.5 Strengths 
There is a widely-held assumption that a prior cancer diagnosis could affect the conduct 
or outcomes of cancer-related studies, despite a lack of conclusive evidence to support 
the claim (Gerber, Laccetti, Xuan, Halm, & Pruitt, 2014). Gerber and colleagues 
reviewed SEER data and found that 80% of 51 lung cancer clinical trials excluded 
patients with a prior cancer diagnosis and 95% among trials with survival as their primary 
endpoint. The researchers estimate that the proportion of participants excluded due to this 
criterion ranged from 0-18% which is larger than the total ineligibility proportion in other 
cancer trials (Gerber et al., 2014). Further research needs to be conducted to better 
understand the implications of this practice, but since neither the PLCO nor NLST 
employed this policy, they provided an excellent opportunity to study the effects of 
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personal cancer history in detail. High quality data collection protocols ensured that data 
was accurate and the amount of missing data was minimized. The number of important 
confounding factors that were able to be adequately controlled for when investigating 
these associations is also unprecedented. Many of the more considerable effects seen 
were for smoking-related cancers. This underlines cigarette smoking as a modifiable risk 
factor for lung cancer. 
This study is of clinical importance in that it suggests that when trying to identify 
those at highest risk for lung cancer, simply establishing whether or not they are a cancer 
survivor is sufficient compared to more sophisticated information, an accurate report of 
which may be difficult to obtain. With respect to research surrounding the risk of second 
primary lung cancer, our study underlines the importance of adjusting for key cofactors, 
particularly smoking-related information which is commonly omitted.  
5.1.7 Future directions 
Future studies should investigate the impact of previous cancer types that were 
considered exclusion criteria for the two screening trials analyzed here (prostate, lung, 
colorectal and ovarian). It may also be prudent to consider relaxing this criterion for 
future lung cancer screening trials. The effects of previous prostate and testicular cancers 
on SPLC risk after adjustment for known lung cancer risk factors require clarification as 
they were inestimable in the current analysis. Clarification is also required as to whether 
the marked increase in risk of SPLC observed among lung cancer survivors persists after 
controlling for other known lung cancer risk factors. Patterns of inaccurate reporting also 
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need to be better understood as well as the reliability of self-reported cancer data as a 
whole (Harlow & Linet, 1989). 
The impact of treatments for previous cancer should be studied in more detail as 
data to assess the factors were not available here. Specifically, to assess whether the use 
of chemotherapeutic agents and/or radiation dose modify the association between a 
personal history of cancer and future lung cancer risk. Little is known about the extent to 
which smoking interacts with ionizing radiation in terms of lung cancer carcinogenesis so 
this also requires further study. Since it has been estimated that around 30% of cancers 
worldwide are attributable to tobacco use, smoking status is considered by some 
researchers as ‘another vital sign’ that ought to be measured at several stages of all future 
oncology trials: at registration, diagnosis, throughout treatment and during follow-up if 
possible (Gritz, Dresler, & Sarna, 2005). 
Future efforts to improve lung cancer risk prediction should pursue alternative 
strategies such as refining risk factors other than personal cancer history or investigating 
novel predictors as candidates for inclusion in future models. 
5.2 Conclusions 
Despite having far lower absolute numbers of cancer survivors compared to studies that 
have used all cases found in cancer registries, this analysis is novel in that no other study 
has evaluated the effects of previous cancers on lung cancer risk after adjustment for 
many important covariates. Contrary to many of the hazardous effects reported for 
specific cancer types in previous studies, relatively few cancer types, save for oral and 
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uterine, were associated with a statistically significant increase in SPLC risk after 
controlling for known lung cancer risk factors. 
No evidence of a trend between the number of previous cancers reported and lung 
cancer risk was seen for the participants of either screening trial. The risk of SPLC 
relative to those with no cancer was not statistically different between those diagnosed 
with an initial cancer before age 60 compared with those whose first cancer was 
diagnosed after 60. 
None of the more sophisticated measures of personal cancer history improved 
lung cancer risk prediction. The original binary measure representing a personal history 
of any cancer demonstrated comparable predictive value to the more refined summary 
variables based on specific cancer types, head and neck cancers only or smoking-related 
cancers. Neither the number of previous cancers nor the age at first cancer diagnosis 
improved prediction when included alongside the established predictors. This more 
sophisticated information regarding personal history does not appear to improve lung 
cancer risk prediction compared to simply capturing its overall presence.  
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